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ABSTRACT 
James M. Dunleavey: PECAM-1-dependent vascular mimicry in melanoma: contributions to 
anti-angiogenic resistance 
 (Under the direction of Andrew C. Dudley) 
 
 The development of a perfused blood vasculature is a requirement both in development 
and for many human pathologies. Critically, the formation of new blood vessels through 
angiogenesis has been identified as a hallmark of cancer progression. A major effort has been 
undertaken to target the blood vessels of nascent and metastatic tumors to inhibit tumor growth. 
Therapies targeting the blood vasculature have shown limited efficacy, and multiple modes or 
resistance have been proposed. While attempting to characterize endothelial cells from mouse 
models of melanoma, we discovered a novel subpopulation of tumor cells expressing the 
endothelial cell marker PECAM-1. PECAM-1+ melanoma participate in a tumor cell derived 
vasculature in a form of vasculogenic mimicry (VM). PECAM-1+ tumor cells form PECAM-1-
dependent vascular-like networks in vitro  and generate perfused vascular networks in vivo in a 
VEGF-independent fashion. Transcriptional activator AP-2a is diminished in PECAM-1+ 
melanoma and represses PECAM-1 expression. Re-expression of AP-2a in PECAM-1+ tumor 
cells blocks PECAM-1 expression and inhibits tube-forming ability, and knockdown of AP-2a 
upregulates PECAM-1 in PECAM-1- tumor cells. We identified PECAM-1+ tumor cells in both 
murine and human melanoma, and propose that PECAM-1+ melanoma cells may instigate VM, 
collaborate with host endothelial cells, and form PECAM-1-dependent vascular channels which 
are refractory to VEGF inhibition.  
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CHAPTER 1: Introduction1 
Tumor angiogenesis as a therapeutic target: A brief history 
Solid tumors require blood vessels for growth, access to oxygen and nutrients, and the 
removal of waste products; and the development of the tumor vasculature has been identified as 
a hallmark of cancer (Hanahan and Weinberg 2000; Hanahan and Weinberg 2011). Early 
research in the 1940s-1960s found that in avascular tumor models, without the development of 
new blood vessels through sprouting angiogenesis. tumor growth was held in check and tumors 
remained <4 mm (Folkman, Cole, and Zimmerman 1966; Algire and Chalkley 1945). This 
observation led Dr. Judah Folkman in 1970 to describe a tumor angiogenesis factor (TAF) which 
was released from tumor cells and elicited strong angiogenic effects in the rat dorsal air sac 
model (Folkman et al. 1971). The observations of the need for vascular development in tumors 
of almost every type led Folkman to propose that “if neovascularization is prevented many solid 
tumors might remain fixed at this [2-3 mm] tiny diameter” (Folkman 1972). Folkman continued 
studying tumor angiogenesis, and in the decades following his proposal the identification of key 
pro-angiogenic molecules including bFGF (Shing et al. 1985), PDGF-β and most notably VEGF 
(Ferrara and Henzel 1989) which was also shown to be secreted by tumor cells shortly after its 
discovery (Rosenthal et al. 1990). The discovery of the pathways responsible for initiating and 
maintaining angiogenesis raised interest in the possibility of targeting the molecules in these 
pathways to blockade angiogenesis. Prevailing theories suggested that as the endothelial cells of 
                                                
1 Chapter 1 is adapted in part from Dunleavey, J.M. and Dudley, A.C. “Vascular mimicry: 
concepts and implications for anti-angiogenic therapy. Current Angiogenesis. 1. 133-138 (2012) 
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the tumor vasculature are derived from the genetically stable host stroma, anti-angiogenic 
therapies should not elicit resistance to treatment as is seen with commonly used cytotoxic 
chemotherapies. Development of anti-angiogenic agents proceeded rapidly through the 1990’s 
and in 2004 the Federal Drug Administration approved bevacizumab, a VEGF ligand-binding 
antibody for metastatic colorectal cancer following a promising phase III clinical trial (Hurwitz 
et al. 2004). Subsequent drugs targeted the tyrosine kinase receptors responsible for binding 
VEGF, primarily VEGFR2, which is largely responsible for the induction of proliferation and 
migration necessary for endothelial cells to form new stable sprouts. However, despite initial 
promising results in preclinical trials, introduction of anti-angiogenic agents to cancer patients 
has shown minor survival benefits compared to control cohorts (Jain 2014; Ellis and Hicklin 
2008; Ellis and Fidler 2010; Y. Cao et al. 2011; Carmeliet and Jain 2011). In contrast, a modified 
antibody fragment of bevacizumab, ranibizumab, has shown high efficacy in treatment of age-
related macular degeneration, where aberrant vascular proliferation causes blindness (Stone 
2006). These results taken together have led the field to conclude that targeting the VEGF axis 
may be effective in non-tumor-related neovascularization, but that the tumor vasculature has 
additional modes of resistance to VEGF blockade and other anti-angiogenesis strategies (Bergers 
and Hanahan 2008; Carmeliet and Jain 2011). 
Modes of tumor vascular development 
Decades of work on tumor blood vessels have confirmed at least six routes by which 
tumors develop a vascular network (Carmeliet and Jain 2011). Most of these processes are 
conserved between physiologic and pathologic vessel development, but several tumor-specific 
modes of neovascularization have been described. These processes: vasculogenesis, 
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angiogenesis, intusussceptive branching, vessel cooption, cancer stem cell-derived endothelium, 
and vascular or vasculogenic mimicry will be summarized in brief. 
Vasculogenesis 
Vasculogenesis, the de novo creation of nascent vessel beds, is thought to contribute to 
tumor vessel development (Carmeliet and Jain 2011). Vasculogenesis is best understood in the 
embryo, where the earliest stages of vascular development occur. Initial studies using embryonic 
stem cells from mouse blastocysts observed the differentiation of stem cells to cystic embryoid 
bodies containing “blood islands”, or nascent vascular beds, which organized into a 
differentiated primitive vascular network (Risau et al. 1988). The derivation of these 
vasculogenic networks from endothelial cell progenitors, termed angioblasts in the embryo, is 
governed by many of the same factors as angiogenesis, including FGF2 (Cox and Poole 2000), 
but primarily is thought to be controlled through VEGF signaling, as Flk1 is prominently 
upregulated in the angioblast population early in vasculogenesis (Risau and Flamme 1995). 
Furthermore, Flk1-deficient stem cells used to generate Flk1 chimeric embryos showed a 
necessity for VEGF signaling through Flk1, as Flk1-/- cells failed to contribute to blood islands or 
nascent vascular beds (Shalaby et al. 1997). In addition to its role in neovascularization in 
embryogenesis, vasculogenesis has been suggested to occur postnatally through the recruitment 
of what were initially termed endothelial progenitor cells (EPCs), and more recently termed 
endothelial colony forming cells (ECFCs). Initial studies identified cells from the mononuclear 
fraction of human peripheral blood expressing the cell surface antigen CD34 which displayed 
endothelial phenotypes when cultured (Asahara et al. 1997). However, there remains a 
controversy whether circulating endothelial cells or their progenitors are involved in tumor 
vascular development.  Gao et al. used GFP-labeled bone marrow introduced to mice following 
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irradiation, and using immunohistochemistry claimed to find 13% of tumor blood vessels derived 
from GFP+ bone marrow (Gao et al. 2008). Furthermore, sex-specific FISH probes in human 
subjects who had received cross-sex bone marrow transplants revealed marrow-derived cells 
from donor marrow expressing endothelial markers in tumor blood vessels, albeit at low 
percentages of total blood vessels examined (Peters et al. 2005). In contrast, previous work from 
our group found that GFP-labeled bone marrow, when transplanted into irradiated mice failed to 
adopt endothelial phenotypes by flow cytometry analysis (Dudley et al. 2010). Furthermore, 
other studies have found little evidence for the incorporation of BMDEC in tumor vessels 
(Purhonen et al. 2008), although they were met with fierce criticism (Kerbel et al. 2008). The 
disparity in these data may be explained by a lack of defining markers for BMDEC (Yoder 2009) 
and the methodologies used. IHC for endothelial markers has a possibility for close overlap with 
non-endothelial BMDC, while the cytometry experiments performed by our group examined 
individual cells. Whether bone marrow-derived progenitor cells actively contribute to tumor 
neovascularization remains one of the major questions facing the field. 
Intussusceptive microvascular growth 
Intussusception, or intussusceptive microvascular growth (IMG), is a process by which 
vessel complexity is thought to increase without the need for endothelial cell proliferation or 
activation. Elegant electron microscopy experiments in 1986 in the rat lung suggested that as the 
lung develops, vessel complexity increases through the formation of “transcapillary pillars”  
which divide pre-existing large vessels into separate capillaries, which was thought to allow 
rapidly growing tissues to increase vascular supply without exponential expansion of the 
endothelium (Caduff, Fischer, and Burri 1986). The rapidity of intussusception in 
embryogenesis, which observational microscopy revealed occurred much more quickly than 
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sprouting angiogenesis, led to the proposal that rapid increases in vessel complexity could aid 
tumor growth. Indeed, early studies in mouse ascites tumors as well as in human tumor 
xenografts demonstrated the formation of tumor blood vessels through pre-existing vessel 
remodeling (Nagy et al. 1995; Patan, Munn, and Jain 1996; Patan et al. 2001), and was observed 
to take place in human glioblastoma patients (Nico et al. 2009). One study has found a 
correlation between resistance to anti-VEGF therapy and increases in transcapillary pillars in the 
tumor vasculature, suggesting a link between IMG and anti-VEGF resistance (Hlushchuk et al. 
2010). Interestingly, IMG has been shown to be upregulated by exposure to erythropoietin (Epo), 
which has been shown to be upregulated in multiple tumor types. However, relatively little is 
known about the role intussusception plays in tumor vascular development, with less than 20 
articles appearing in PubMed on the topic (as of February 2016). It remains to be seen what role 
this process plays in tumor angiogenesis, and whether discrete pathways independent of those 
regulating angiogenesis exist for potential therapeutic targeting. 
Vessel cooption 
Perhaps the simplest way for tumors to enhance their vascular network is to take 
advantage of pre-tumor physiologic angiogenesis in what has become known as vessel cooption. 
Simply put, tumors grow along and engulf host blood vessels without the need for generating 
new vessels. Vessel cooption was initially described in 1999, where it was found that in a rat 
glioma model, early grade tumors >1mm grew along what appeared to be normal blood vessels 
and had used these vessels to become perfused. As the tumors progressed, however, these vessels 
regressed and were partially supplanted by sprouting angiogenesis, which was suggested to be 
driven by antagonism of Tie2 by angiopoetin-2 (Ang2), triggering erosion of pre-existing vessels 
followed by VEGF-driven sprouting. Notably, Ang2 has been shown to be upregulated in the 
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coopted vessels of early tumors (Holash et al. 1999). Ang2 was shown to inhibit tumor 
angiogenesis when overexpressed, which would support a role for it contributing to erosion of 
pre-existing vessels in wild-type tumor models (Lee et al. 2006; Y. Cao et al. 2007).  Donnem 
and colleagues surveyed the literature recently and found a large number of studies identifying 
vessel cooption by tumors, largely in those tumors which originate in highly vascular organs 
such as the brain and lung (Donnem et al. 2013). They and others have suggested that vessel 
cooption represents a potent mechanism by which tumors can obtain access to the blood 
vasculature without initiating angiogenesis (Donnem et al. 2013; Carmeliet and Jain 2011). 
Interestingly, murine and human studies in glioblastoma have shown that VEGF blockade 
decreases blood vessel density but vessels remaining post-treatment morphologically resemble 
those of the normal brain, suggesting that angiogenesis-independent cooption of normal 
vasculature might contribute to resistance to conventional anti-angiogenic therapies (Rubenstein 
et al. 2000; Norden et al. 2008). Therefore, to truly inhibit vascularization of tumors, it may be 
necessary to target mature, nonangiogenic vessels within the tumor in addition to blocking 
neoangiogenesis. Supporting the theory that cooption is a “fallback” absent angiogenesis, recent 
data implicating a microRNA cluster (miR-143/145) in tumor neoangiogenesis found that in the 
absence of tumor angiogenesis tumor vessels have the characteristic honeycomb structure of 
alveolar blood vessels. This phenotype suggests that impairment of the angiogenic switch may be 
ameliorated by vascular cooption (Dimitrova et al. 2016). Studies are currently underway testing 
antagonism of Ang2, and initial reports suggest dual targeting of Ang2 alongside VEGF may 
improve the efficacy of anti-angiogenesis strategies, but clinical data has not yet been shown to 
validate Ang2 antagonists as a valid strategy in human cancer patients. Better understanding of 
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the gene signatures and complexity of mature coopted vessels could perhaps yield new druggable 
targets in conjunction with existing targeting strategies. 
Angiogenesis 
Perhaps the best studied of any mode of tumor vessel development is sprouting 
angiogenesis. Since the initial description of branched sprouts in tumors implanted in the 
avascular corneal pocket tumor model, the formation of vessels through the extension of sprouts 
from the pre-existing vasculature to perfuse the tumor has been one of the most intensively 
studied aspects of tumor biology, and targeting angiogenesis has seen dozens of new drugs 
brought through clinical trials (Jain 2014). The basic biology of tumor angiogenesis is thought to 
mirror normal physiologic angiogenic vessel development.  
Folkman observed that tumors without a vessel network could only reach a volume of 
~4mm. Once a tumor reaches this size, it is proposed that the core of the tumor cannot be 
sustained by the diffusion of oxygen and nutrients from the peripheral blood vessels. The 
formation of this hypoxic core stimulates hypoxic response factors, notably the HIF family of 
proteins, which drive the upregulation and subsequent release of potent endothelial mitogens 
including VEGF-A (VEGF) (Dor, Porat, and Keshet 2001), and bFGF (Calvani 2006; Krock, 
Skuli, and Simon 2012) among many others (reviewed in depth by M.C. Simon and colleagues 
(Krock, Skuli, and Simon 2012)). These soluble factors create gradients of chemokines which 
work in concert to stimulate the process of sprouting angiogenesis, which I will summarize in 
brief. The most studied and best understood pathway for neoangiogenesis is mediated through 
the VEGF pathway. Sprout initiation is thought to begin by upregulation of VEGF ligand in the 
extracellular environment leading to ligand binding of VEGFR2, which is enhanced by the 
binding of VEGF co-receptors neuropilin 1 and 2 (Soker et al. 1998). As an alternative or 
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perhaps as an additive process, VEGF-C has been shown to bind VEGFR3/Flt4 along with NRP2 
to trigger sprouting in lymphatic vessels.  While VEGFR3 signaling is not sufficient to induce 
angiogenesis in tumors, if activated alongside VEGFR2 it is sufficient to sustain tumor 
angiogenesis even after VEGFR2 blockade (Tammela et al. 2008). However VEGF-VEGFR2 
signaling is thought to be the primary pro-angiogenic signal from tumors, and will henceforth be 
referred to as VEGF signaling. Following phosphorylation of the tyrosine kinase receptor, 
endothelial cells initiate signaling programs which increase cell motility and proliferation while 
also stimulating upregulation of Notch ligand DLL4, allowing for lateral signaling to 
neighboring endothelial cells inhibiting further sprouts from forming (Siekmann and Lawson 
2007). Notch has been shown to downregulate VEGFR2, suggesting that following the activation 
of a sprout initiating cell, lateral inhibition through Notch/Dll4 could prevent neighboring cells 
from receiving VEGF signals, allowing spatial regulation of tip formation (Williams et al. 2006). 
This selectivity allows an individual sprout to form, wherein the tip cell degrades the basement 
membrane and migrates towards the VEGF gradient. Furthermore, the VEGF gradient is 
continually refined in part through secretion of a soluble form of VEGFR1/Flt1 (sFlt1), which 
binds and sequesters the VEGF ligand without inducing signaling events (Chappell et al. 2009). 
The specificity of the VEGF gradient allows for a high degree of targeting by the nascent sprout, 
which can extend into the avascular space and later fuse with other sprouts or mature vessels 
through anastomosis.  
 It should be stressed that VEGF is by no means the only factor governing angiogenesis. 
Dozens of extracellular and intracellular cues regulate sprout initiation and maintenance. 
However, VEGF occupies a unique position in the field of anti-angiogenesis strategies due to 
several factors. Perhaps the most striking reason for the focus on VEGF can be traced to initial 
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loss-of-function genetic experiments wherein inactivation of just one allele of Vegf resulted in 
embryonic lethality and striking vascular defects (Ferrara et al. 1996; Carmeliet et al. 1996). 
These discoveries led Napoleone Ferrara and others to target the VEGF pathway in tumors, that 
in preclinical models showed striking success at inhibiting tumor vascular development and 
growth (Borgström et al. 1996; Borgström et al. 1998; Warren et al. 1995; Ferrara 2002). The 
success of agents specifically designed to target angiogenesis in preclinical models led to a boom 
of drugs targeting both VEGF ligand (bevacizumab, aflibercept, ranibizimab, pegaptanib) and 
receptors (sunitinib, sorafenib, pazaponib, vandetanib). With the introduction of these drugs 
there have been great successes in treatment of vascular-associated pathologies. Notably, 
ranibizimab and aflibercept were both approved for treatment of age-related macular 
degeneration (ARMD) (while bevacizumab has been used off-label for this condition), and have 
been highly successful at restoring vision in patients with this condition (Rodriguez et al. 2012; 
Michels et al. 2005). While the results for ARMD have been generally positive, it has been 
shown that VEGF is necessary for maintenance of Müller cells as well as the photoreceptors of 
the eye, which casts doubt on the long term efficacy of blockading VEGF (Saint-Geniez et al. 
2008). If non-endothelial ocular cells rely on VEGF, sustained blockade of VEGF ligand could 
damage vision independent of the aberrant neoangiogenesis seen in ARMD. Therefore, even in 
conditions where anti-angiogenic therapies have been seen as unadulterated successes, there are 
important considerations to be made about efficacy and long term strategies using these drugs. 
 The successes at targeting neoangiogenesis in ARMD are tempered by the relative lack of 
success of anti-VEGF therapies in tumor patients. While the initial phase III clinical trial for 
bevacizumab in colorectal cancer resulted in ~3 month increases in patient progression free 
survival (Hurwitz et al. 2004), subsequent clinical trials and clinical data have revealed that the 
 10 
benefit of anti-angiogenic therapies in patients is modest (Jain 2014). The question posed by the 
lack of success in anti-angiogenesis research boils down to: is the tumor vasculature more 
complex than initially thought? Numerous studies following the introduction of anti-VEGF 
therapies have confirmed that there are multiple ways in which tumors can resist blockade of 
neoangiogenesis. One major hypothesis to explain the discrepancy between preclinical modeling 
of anti-VEGF agents and patient responses is the lack of predictive capability of non-human 
modeling of tumor growth (Ellis and Fidler 2010). Ellis and Fidler suggest that the prevailing 
models of cancer used for decades fail to physiologically capture the complexity of human 
tumors. Notably, the injection of boluses of tumor cells fails to recapitulate the potentially 
decades-long evolution of a tumor from a distinct originating cell. More importantly for anti-
angiogenesis modeling, the implantation of a large mass of tumor cells would be predicted to 
immediately induce hypoxic signaling through HIF-1α and HIF-2β, and that the resulting tumor 
would be more reliant on neoangiogenesis than other modes of vascularization which may be 
more common in human patients. Therefore, preclinical modeling in mice, especially those 
preclinical models used in the early stages of anti-angiogenesis testing, may have generated 
results that did not accurately forecast patient responses. Fortunately, there have been advances 
in mouse models of cancer which might improve pre-clinical modeling, although whether the 
complexity of the decades of tumor development in human patients can be accurately modeled 
on a shorter time scale remains to be seen (Eklund, Bry, and Alitalo 2013; M. Singh and Ferrara 
2012; Francia and Kerbel 2010).     
Tumor-specific vascular development 
It should be noted there is no clear delineation between the acquisition of endothelial 
characteristics by tumor cells (vascular mimicry) and the differentiation of multipotent cancer 
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stem cells (CSCs) into endothelial cells. It is possible that the two processes are in fact stages on 
a sliding scale of tumor self-vascularization. However, there is no clear linkage of the these two 
concepts and the field currently treats them as separate modes of tumor vascular development 
(Carmeliet and Jain 2011), therefore I will discuss them individually.  
Cancer stem cell differentiation into endothelial cells 
The existence of cancer stem cells or tumor initiating cells has been demonstrated in 
multiple models, although controversy has existed as to the rarity and consequences of tumor 
cells differentiating into multiple cell lineages. Initially it was proposed that these tumor-
initiating cells were rare, self-renewing cells which mirrored tissue specific stem cells seen in 
non-tumor conditions. Multiple studies identified rare, tumor initiating cells in colon (Ricci-
Vitiani et al. 2006), brain (S. K. Singh et al. 2004), breast (Ponti et al. 2005), skin (Schatton et al. 
2008), pancreatic (Adikrisna et al. 2012), head and neck (Prince et al. 2007), ovarian (S. Zhang, 
Balch, et al. 2008), lung (Eramo et al. 2007), and prostate (Collins et al. 2005) cancers, and have 
been proposed to be extremely rare (between 1:980 cells to >1:100,000 cells) (Ishizawa et al. 
2010) using immunocompromised mice xenograft studies. In contrast, one study found that using 
NOD/SCID Il2rg-/- (NSG) mice, melanoma tumor initiating cells were relatively common (up to 
1:5 cells), and suggested that older studies reliant on different mouse models may be flawed 
(Quintana et al. 2008), while concurrent studies in pancreatic xenografts in NSG recapitulated 
the rare cell phenotype in NSG mice (Ishizawa et al. 2010). These competing hypotheses may be 
explained by variations between cancers with different cells-of-origin or through experimental 
variations, but the rarity of tumor stem cells does not necessarily correlate with the sustained 
growth of tumors, leading one group to distinguish between tumor initiating stem-like cells and 
“tumor-propagating cells” that allow for the continued growth of the tumor (Kelly et al. 2007). 
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Regardless of the rarity of cancer stem cells, it has been shown in several seminal studies that 
CD133+ tumor stem cells are capable of transdifferentiating into endothelial or endothelial-like 
cells, and they form part of the vasculature in tumors, notably glioblastoma and breast cancer 
(Wang et al. 2010; Ricci-Vitiani et al. 2010; Bussolati et al. 2008). To what degree these 
endothelial cells are in fact bona fide endothelium and whether they retain tumorigenicity and 
other tumor-specific properties remains unknown. Importantly, one group found that in vitro, 
tumor derived endothelial cells were unresponsive to VEGF stimulation or blockade, suggesting 
there are fundamental differences between bona fide EC and their tumor-derived counterparts 
(Soda et al. 2011). 
Vascular mimicry 
Discovery and controversy 
Vascular or vasculogenic mimicry (VM) was initially described in aggressive, uveal 
forms of melanoma as a process of “dedifferentiation” of tumor cells into an “endothelial-like” 
phenotype (Maniotis et al. 1999). In these tumors, VM was identified as periodic acid-Schiff 
(PAS) positive, matrix-associated channels devoid of bona fide endothelium. VM channels 
appeared to contain erythrocytes and were therefore hypothesized to connect with the existing 
vasculature. Notably, patients displaying the presence of PAS-positive networks in their tumors 
had an increased mortality compared to those patients which did not. Following this observation, 
it was suggested that some tumors were capable of forming their own vascular channels which 
could carry blood, oxygen and nutrients in collaboration with blood vessels formed by 
conventional routes of tumor angiogenesis (i.e. sprouting). The clinical implications for VM 
were clear: VM-forming tumors were more virulent than their non-VM counterparts and VM-
lined channels might not respond predictably to conventional anti-angiogenic therapies. 
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These seminal VM studies were met with criticism at two fronts (McDonald, Munn, and Jain 
2010). First, the novelty of the findings was challenged. For example, tumor cell-lined “blood 
lakes”, were identified in uveal melanoma over 40 years prior to the work by Hendrix (Francois 
1963; Jensen 1964; Jensen 1976; Francois and Neetens 1967). However, it was not understood at 
that time that these “blood lakes” were not always physically connected with the vasculature; 
instead, “blood lakes” were typically formed by erythrocytes which had leaked from poorly 
formed tumor vessels into the surrounding area (Prause and Jensen 1980; Hammersen, Endrich, 
and Messmer 1985). Second, the relevance of these findings was questioned, considering the 
possibility that VM channels were not functional. Moreover, there were serious technical 
limitations in identifying VM channels using conventional immunohistochemistry, which was 
prone to artifacts and not entirely objective. 
At the same time VM was identified by Hendrix, an alternative mode of tumor cell-
originated vasculature was proposed. “Mosaic vessels”, whereby tumor cells enter the luminal 
space of host-derived vasculature were initially described in mouse xenografts of labeled human 
colon cancer specimens (Chang et al. 2000). Like VM, the concept of mosaic vessels was 
controversial. It was unclear whether tumor cells were functioning within the vessel wall or were 
merely an artifact of tumor cells closely positioned near blood vessels or shed into the 
circulation. Mosaic vessels contrasted the concept of VM, where an entire vascular channel is 
lined solely by tumor cells, masquerading as endothelium. As concepts, VM and mosaic vessels 
are not mutually exclusive, and it is possible that both modes of tumor angiogenesis can co-exist 
within the same tumor (Fig. 1.1).   
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Figure 1.1: Models for tumor-cell-derived vasculature 
A) a normal tumor blood vessel lined by vascular endothelial cells B) mosaic vessels where 
tumor cells collaborate with pre-existing endothelium. Tumor cells (shaded) participating as 
mosaic vessels passively fill in gaps within blood vessel walls. Mosaic tumor cells may co- opt 
the anti-coagulant properties of existing endothelium and may not express endothelial cell-
selective markers C) vascular mimicry, whereby tumor cells actively and autonomously create 
new vessels in the absence of vascular endothelium. These channels are comprised of tumor cells 
which may acquire features of endothelial cells including expression of endothelial-selective 
markers, some anti-coagulant properties and ability to transport blood and fluid. Tumor cells, 
with properties of VM, may also collaborate with co-opted, pre- existing vessels to form hybrid 
tumor blood vessels.  
 
Recently, VM has re-entered the spotlight in angiogenesis research following the 
publication of several high-profile research articles on this topic (Wagenblast et al. 2015; Soda et 
al. 2011) ; see also commentaries by Bautch and Hendrix (Bautch 2010; Hendrix 2015). 
Importantly, the presence of VM channels in patient samples has recently been shown to predict 
poor clinical outcomes (Yang et al. 2016; Z. Cao et al. 2013). Irrespective of the advances made 
in VM research, relatively little is known about the molecular mechanisms and clinical 
manifestations of VM. Moreover, how VM might impact the effectiveness of anti-angiogenic 
therapies is not understood. 
Characteristics of vascular mimicry 
Tumors of vascular origin including hemangioma, angiosarcoma, and Kaposi’s sarcoma 
originate from transformed vascular cells. These tumors, as expected, are highly vascularized, 
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they are pathologically “bloody,” and they are characterized by tangles of poorly formed, 
atypical vascular structures. In contrast, VM typically designates expression of endothelial 
factors and acquisition of vascular cell characteristics by tumor cells of a non-vascular origin. 
Following its initial discovery in uveal melanoma, VM has now been identified in breast 
(Shirakawa et al. 2002; Wagenblast et al. 2015), ovarian (Sood et al. 2010; Sood et al. 2002), 
prostate (Sharma et al. 2002), Ewings sarcoma (van der Schaft 2005), hemangiopericytoma (Z. 
Zhang et al. 2011), astrocytoma (Liu et al. 2011), hepatocellular carcinoma (Guzman et al. 
2007), glioblastoma (Wang et al. 2010; Soda et al. 2011; Ricci-Vitiani et al. 2010; Hallani et al. 
2010) and lung (Passalidou et al. 2002) cancers. Thus, VM has been described in tumors 
originating from all three germ layers: ectoderm, mesoderm and endoderm. These findings 
suggest there may be strong selection pressure for VM within the pool of malignant cells 
irrespective of cellular ontogeny. Supporting this, in a recent high-profile study of breast cancer 
heterogeneity, the presence of VM-competent clones in a tumor allowed for efficient 
intravasation by tumor cells (Wagenblast et al. 2015). A survival advantage may be afforded to 
tumor cells with greater plasticity and the ability to form their own vascular networks in the face 
of nutrient and oxygen scarcity characteristic of the tumor microenvironment. Indeed, hypoxic-
conditioning of tumor cells promoted their alignment into structures resembling blood vessels 
and upregulated expression of the endothelial markers vWF and CD31 (Soda et al. 2011). 
Additionally, hypoxic culturing of VM tumor cell lines increases the expression of a number of 
endothelial-like factors, including laminin 5 γ2-chain, laminin 411, and EphA2 (R. E. Seftor et 
al. 2001; Hess et al. 2006; Larson et al. 2014). 
Here, I have identified three common characteristics of VM networks in cancer that I 
consider to be cardinal features of the VM phenotype: expression of endothelial-selective 
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makers, expression of anti-coagulant factors, and anastomosis/perfusion with the existing 
vasculature. While these defining characteristics may be common, unifying features of VM, this 
list is not all-inclusive. Furthermore, VM tumors need not simultaneously display each of these 
characteristics. For example, tumor-derived channels which connect with the circulation and 
carry fluid, even without expression of endothelial-selective markers, would embody the 
definition. 
Expression of endothelial-selective markers 
Some tumor cells which participate in VM express typical vascular cell markers (E. A. 
Seftor, Meltzer, Schatteman, et al. 2002; E. A. Seftor, Meltzer, Kirschmann, et al. 2002; Bittner 
et al. 2000). Expression of VE-cadherin (Hendrix et al. 2001), EphA2 (Hess et al. 2006), CD34 
(Soda et al. 2011), and CD31 (Soda et al. 2011) have been described in VM tumors. However, 
these markers are all selective for and not specific to the vascular endothelium. For example, 
cells of hematopoietic origin including monocytes, neutrophils, and lymphocytes also express 
CD31 and CD34. In some cases, expression of these markers by tumor cells may be a “rough 
attempt” at tumor cell differentiation into vascular-like cells (Pisacane, Picciotto, and Risio 
2007). In support of this possibility, VM tumors do not behave predictably in response to 
treatment with typical endothelial cell mitogens. For example glioblastoma, with features of VM, 
lack expression of VEGF and bFGF receptors (Soda et al. 2011). The ligands for these receptors 
are potent endothelial cell mitogens and are indispensable for the survival of bona fide 
endothelium but may not be necessary for survival of VM tumor cells whose growth is driven by 
oncogenes. Furthermore, VEGF and bFGF failed to elicit the formation of VM channels, 
suggesting that factors which are ordinarily pro-angiogenic during development and pathological 
neovascularization do not necessarily control VM responses (Maniotis et al. 1999). On the other 
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hand, recent work from the Ellis lab demonstrated expression of VEGFR-2 in ovarian cancer, 
although it was not determined whether this played a direct role in VM (Spannuth et al. 2009). 
More recently Rong Shao’s group found that VEGFR-2 was involved in VM in a VEGF-
independent manner (Francescone et al. 2012; Scully et al. 2012), although the mechanism was 
unclear. However, expression of VEGF receptors (and other “vascular-like” factors) by tumor 
cells may not necessarily confer a VM phenotype but may instead reflect acquisition of a 
survival pathway normally related to endothelial function and development. Good examples are 
members of the Notch/Nodal pathway commonly involved in embryonic morphogenesis but also 
involved in the regulation of cellular plasticity in aggressive forms of uveal melanoma 
(Topczewska et al. 2006; Conway, Collen, and Carmeliet 2001; Khalkhali-Ellis et al. 2014). 
Expression of anti-coagulant factors 
A major function of vascular endothelium is control of hemostasis, which is achieved by 
the expression of anticoagulant proteins including tissue factor pathway inhibitors (TFPIs), 
heparin sulfate proteoglycans, and thrombomodulin at the luminal surface (Pober and Sessa 
2007). Blood will coagulate instantaneously when in contact with most tumor cells in the 
absence of anti-clotting factors (Shoji et al. 1998). Thus, it might be predicted that tumor cells 
which participate in VM would express anticoagulant factors, or otherwise inhibit clotting by 
another mechanism. Indeed, some aggressive VM-forming tumors, but not their non-VM 
counterparts, express proteins involved in the coagulation cascade including TFPI-1 and TFPI-2 
(Ruf et al. 2003). Expression of these factors has been detected in VM networks where it is 
assumed their activity is necessary to allow blood to flow freely by preventing tissue factor-
mediated clotting. The presence of anti-coagulant cell-surface markers, coupled with the 
identification of circulating erythrocytes in the initial discovery of VM, suggests that these 
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channels may play an active rather than a passive role in fluid transport. While it may be 
essential that VM channels lined entirely by tumor cells express some proteins of the anti-
coagulant system, it is less certain if VM tumor cells which collaborate with host endothelium 
(e.g. mosaic vessels) require their own anti-coagulant proteins to conduct fluid, or if they can co-
opt those of the tumor endothelium. Furthermore, in a study examining breast cancer 
heterogeneity, the expression of two anti-coagulant genes, Slpi and Serpine2 was sufficient to 
allow tumor cells to engage in vascular mimicry, and the authors found this VM was able to 
allow for efficient intravasation and escape of tumor cells from the primary tumor site as well as 
maintain tumor blood flow (Wagenblast et al. 2015). 
Anastomosis with perfused vasculature 
Initial discoveries of VM were met with skepticism because it was not believed that 
tumor cell-lined channels were physically connected with perfused tumor blood vessels. Instead, 
VM was mostly dismissed as an artifact of tissue sectioning or was ascribed to pooling of 
erythrocytes in “blood lakes” which were not physically connected with the vasculature. 
Definitive proof for functioning VM channels has been difficult to establish due to the low 
fidelity of imaging systems which does not allow for sufficient resolution. For example, the 
tumor endothelium is typically “squeezed” by the overlying mass of tumor cells resulting in thin, 
flattened endothelial nuclei which can be difficult to view under standard microscopy (Jain, 
Munn, and Fukumura 2002). One common approach for demonstrating VM is through the use of 
fluorescent dyes injected via the tail vein. In one study, fluorophore-conjugated lectin injected 
intravenously co-localized with GFAP+ glioblastoma cells which is good evidence that the tumor 
cells were in contact with flowing blood (Soda et al. 2011). Recently, several studies have used 
advanced imaging techniques including MRI and fluorescent dyes to demonstrate that VM 
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channels are definitively anastomosed with the vasculature and they exhibit blood flow (Clarijs 
et al. 2002; Kobayashi et al. 2002; Frenkel et al. 2007). Additionally, injected microbubbles 
viewed with Doppler imaging revealed a functional connection between host vasculature and 
VM channels (Ruf et al. 2003). 
Origins of vascular mimicry 
Highly aggressive, uveal forms of melanoma have served as the VM prototype. These 
tumors display a high degree of plasticity and cellular heterogeneity which has often been 
interpreted as a recapitulation of the embryonic stages of development related to the de-
differentiation of tumor cells into a more primitive phenotype (E. A. Seftor, Meltzer, 
Schatteman, et al. 2002; E. A. Seftor, Meltzer, Kirschmann, et al. 2002; Bittner et al. 2000). 
Evidence for this is given by the genetic signature of some uveal melanoma tumors which reveal 
loss of melanoma-specific markers including melanoma-cell adhesion molecule and 
micropthalmia-associated transcription factor and gained expression of markers for cells of 
diverse origins, especially vascular cells. Remarkably, this plasticity is reversible and 
reprogrammable by transplanting melanoma cells into an embryonic microenvironment (Hendrix 
et al. 2007). For example, melanoma cells implanted in ovo adjacent to the neuronal crest of 
embryonic chicks did not form tumors and regained expression of a melanocyte-specific 
phenotype marker (MART-1) and the neuronal marker Tuj1 (Kulesa et al. 2006). Thus, cues 
within the microenvironment are capable of instructing melanoma cells to reacquire features of 
cell types derived from the neural crest, their ancestral cell-of-origin. Furthermore, activation of 
CD44, which has been implicated in tumor endothelial cell activation (Griffioen et al. 1997), has 
been shown to activate VM phenotypes in Ewings sarcoma, which suggests there may be 
parallels between tumor EC and tumor cells engaging in VM (Paulis et al. 2015). 
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A second possibility is that CSCs, which are not lineage restricted, are the cell-of-origin 
for some tumor cells with VM characteristics. Theoretically, CSCs would have the potential to 
differentiate to form cells with multiple phenotypes and multiple functions. For example, many 
of the factors associated with stem cell maintenance and renewal such as Notch, Wnt, ABCB5, 
CD133, CD166, nestin, and c-kit, are over-expressed in aggressive cancers displaying a VM 
phenotype (Hendrix et al. 2003; Hoek et al. 2004; Weeraratna et al. 2002; Klein et al. 2006; 
Frank et al. 2005). 
Similar to melanoma, CSC or “CSC-like” cells are reported to form blood vessels in 
aggressive glioblastoma. For example, CD133+/CD144+ glioblastoma stem-like cells (GSC) 
were reported to undergo differentiation into endothelium which was blocked by γ-secretase 
inhibitors or Notch1 silencing (Wang et al. 2010). These tumor-derived endothelial cells carried 
glioblastoma-specific chromosomal aberrations, were not sensitive to VEGF inhibition, and 
contributed substantially to the tumor vasculature (range of 20–90% of TEC). Moreover, GSC-
derived blood vessels were functional because their selective depletion dramatically impaired 
tumor growth. Because a significant proportion of the vasculature may be of neoplastic origin in 
some tumor types, it is possible that these tumors would not respond predictably to conventional 
angiogenesis inhibitors. Moreover, rare CSC with an inherent ability to differentiate and form 
endothelial-like cells may be selected for in response to angiogenesis inhibition. Thus, it is 
feasible that VM may underlie tumor escape and vascular rebound following an initial vessel 
pruning response after treatment with drugs such as bevacizumab. 
Can VM underlie resistance to anti-angiogenic therapies? 
Anti-angiogenic therapy advocates posited that if the tumor’s “plumbing” could be 
selectively eliminated, so could access to oxygen and nutrients. Inhibition of tumor-associated 
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blood vessels would also eliminate the principal routes of metastasis. However as outlined 
above, inhibitors of angiogenesis have demonstrated limited efficacy at inhibiting tumor growth 
while effectively blocking angiogenesis in non-tumor diseases. VM offers one attractive and 
feasible mechanism for a drug resistance paradigm following the use of angiogenesis inhibitors. 
Indeed, melanoma tube-forming ability was completely unaltered by the prototypical 
angiogenesis inhibitor, endostatin, whereas normal endothelial cells were strongly inhibited (van 
der Schaft et al. 2004). 
Initially, anti-angiogenic treatment is thought to be successful because it targets and 
destroys bona fide endothelium. One consequence of angiogenesis inhibition is the exacerbation 
of hypoxia, which creates selection pressure for hypoxia-tolerant tumor cells and stimulates 
expression of factors (e.g. VEGF) which support vessel regrowth. Interestingly, VM-positive 
Ewings sarcoma were closely localized with areas of hypoxia, suggesting the VM may be a 
response to inadequate vascularization by normal angiogenic processes (van der Schaft 2005). 
Indeed, knockdown of VEGF-A in melanoma xenografts reduced tumor growth in some cell 
lines but increased the frequency of VM, which was attributed to increased hypoxic signaling 
(Schnegg et al. 2015). Whereas vascular endothelium may be responsive to VEGF inhibition, 
some tumor cells participating in VM may not be dependent on VEGF for survival, so it is 
unlikely that therapies which trap and inactivate VEGF would be very effective at targeting these 
cells. In fact, the initial discovery of VM revealed that it was insensitive to VEGF stimulation 
(Maniotis et al. 1999). In further support of this theory, AG28262 (a selective inhibitor of 
VEGFR-1, R-2 and R-3) had no effect on in vitro tube formation or percentage of glioblastoma 
tumor-derived vessels in vivo (Soda et al. 2011). On the other hand, thalidomide, an angiogenic 
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inhibitor which is not believed to interfere with the VEGF pathway, could eradicate VM 
channels in melanoma in vivo (S. Zhang, Li, et al. 2008). 
Perspective 
The concept of VM, initially met with skepticism, has received renewed attention in the 
field of angiogenesis research. As studies highlight the disappointing, and unexpected 
consequences of angiogenesis inhibition in tumors, it is tempting to speculate that VM may be an 
underlying, perhaps overlooked mechanism of escape to these therapies (Ruf et al. 2003; Jain, 
Munn, and Fukumura 2002; Bergers and Hanahan 2008). A PubMed search of “vascular 
mimicry” returns ~419 articles dating back to 1999, with almost 300 articles being published in 
the last 5 years and recently a burst of high profile studies provide new evidence supporting the 
existence of VM. Furthermore, while VM was initially described in aggressive forms of uveal 
melanoma, the list of tumor types displaying characteristics of VM is growing. Still, there are 
many remaining questions. For example, does VM play a substantial role in metastasis? Do 
tumor cells form their own lymphatic vessels using processes similar to VM (lymphangiogenic 
mimicry)? And finally, if tumors can self-vascularize, is an anti-angiogenic approach for 
shrinking solid tumors feasible? 
As we learn more about the molecular mechanisms and genetic signature of VM, it is 
possible that tumors could be segregated as likely or unlikely to respond to angiogenesis 
inhibition. Moreover, it is not expected that all tumor types would have the intrinsic ability to 
carry out VM and these tumors might respond favorably to anti-VEGF or other anti-angiogenic 
inhibitors. Thus, VM may not be an intractable problem for cancer therapy but yet another 
complex adaptation of cancer cells struggling to survive in the face of nutrient and oxygen 
scarcity. Interestingly, a recent publication by the discoverer of vascular mimicry, Mary Hendrix, 
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describes a novel therapeutic aimed at targeting VM with a small molecule inhibitor, which 
could be used in conjunction with anti-angiogenic strategies to block tumor vascular 
development on multiple axes (Hendrix, Seftor et al.. 2016). 
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CHAPTER 2: Identification of PECAM-1+ subpopulations of melanoma2 
Introduction 
As introduced in CHAPTER ONE, the development of anti-angiogenic therapies to 
attack tumor-associated blood vessels has been a large field of study for several decades. As anti-
angiogenic drugs are designed to target vascular endothelial cells, they should be active against a 
spectrum of cancers. While preclinical modeling has shown success in blocking tumor growth 
with these agents, data from clinical trials has shown less success in patients. VM, initially 
described in aggressive forms of uveal melanoma, has been documented in multiple tumor types. 
However, the different molecular mechanisms which generate VM-competent tumor cells are 
unclear, and how tumor cell-lined conduits are formed and connected with host vasculature is 
undetermined. Furthermore, it remains controversial whether tumor cells actively engage tumor 
blood vessels or if they simply fill in gaps between neighboring EC in a passive manner. 
Bona fide TEC may be identified and isolated from collagenase-dispersed tumors using 
intercellular adhesion molecule 2 (ICAM2) or platelet EC adhesion molecule (PECAM-1, also 
known as CD31) antibodies followed by immunomagnetic separation (Dudley et al. 2008). Using 
this methodology I uncovered a novel subpopulation of PECAM1+ tumor cells in melanoma that 
participate in a PECAM-1-dependent form of VM. Unlike previous models suggesting that 
tumor cells contribute to neovascularization through endothelial-like differentiation or 
recapitulation of developmental plasticity, I demonstrate the VM-competent tumor cells exist as 
                                                
2 Chapter 2 is adapted in part from Dunleavey, J.M. et al. Vascular channels formed by 
subpopulations of PECAM1+ melanoma cells. Nature Comm. 5. 1-16. (2014) 
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stable, yet hidden subpopulations in heterogeneous melanomas (Wang et al. 2010, Hendrix et al. 
2003, Francescone et al. 2012). Clean separation of PECAM-1+ and PECAM-1- clonal 
populations from the same tumor has allowed us to compare and contrast the differential role 
these two populations have during tumor growth, angiogenesis, and responses to anti-angiogenic 
therapy. 
Results 
Identification of PECAM-1+ tumor cells from B16F10 melanoma 
Using PECAM-1 immunomagnetic separation of collagenase-dispersed B16F10 
melanoma allograft (Dudley et al., 2008; Xiao, Harrell, Perou, & Dudley, 2013; Xiao, McCann, 
& Dudley, 2015), we enriched a PECAM-1+ population to ~ 98% purity, as determined by flow 
cytometry (Fig. 2.1a, b). Compared to the PECAM-1− fraction, the enriched PECAM-
1+ population expressed abundant PECAM-1 mRNA by semi-quantitative RT-PCR (Fig. 2.1c). 
Unexpectedly, VE-cadherin mRNA was not detected in the PECAM-1+ fraction, in contrast to 
mouse dermal endothelial cells (mEC) used as a positive control (Fig. 2.1c) (Dudley et al., 2008). 
However, the PECAM-1+ fraction strongly expressed the melanocyte marker tyrosinase (Tyr) 
leading us to suspect we had enriched a previously unidentified PECAM-1+ subpopulation of 
melanoma cells from the B16F10 cell line. To test this possibility, we engrafted parental 
B16F10-GFP tumor cells into wild type, C57BL/6 mice and unlabeled B16F10 cells into 
C57BL/6-Tg(CAG–EGFP)1Osb/J mice. We then used PECAM-1 immunomagnetic separation to 
retrieve highly purified fractions as before. The results showed that B16F10-GFP tumor cells in a 
wild type host generated PECAM-1+/GFP+ cells whereas wild type tumors in a GFP host 
generated PECAM-1+/GFP− cells (Fig. 2.1d). These results are consistent with a tumor cell-of-
origin for the PECAM-1+ cells we have isolated. Furthermore, these results appear to rule out the 
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possibility of fusion between tumor cells and PECAM-1+ vascular EC in this particular mouse 
tumor model. 
Next, we determined the proportion of PECAM-1+ tumor cells in B16F10 tumors in vivo 
using flow cytometry. Tumors were harvested once they had reached ~ 0.4 g (+/− 0.26 g, s.e.m.) 
or ~ 1.0 g (+/− 0.22 g, s.e.m.) in size. The proportion of PECAM-1+ tumor cells remained at ~ 
0.2% of the total cellular pool, irrespective of tumor size. After gating out CD45+ hematopoietic 
cells, the ratio of PECAM-1+ vascular EC to PECAM-1+ tumor cells was approximately 10:1 
(Fig. 2.1e, f). Taken together, these results suggest that subpopulations of melanoma cells may 
express the vascular cell adhesion molecule PECAM-1 in vivo. 
Isolation of PECAM-1+ clonal populations from B16F10 melanoma 
PECAM-1+ cells comprised a minor fraction of B16F10 cultures and could not be easily 
detected by flow cytometry. However, occasional clusters of PECAM-1+ cells could be found 
under fluorescence microscopy when B16F10 cultures were directly stained with PECAM-1 
antibodies (Supplementary Fig. 2.1a). To further explore the significance and biological 
functions of PECAM-1+ melanoma cells, we prepared clonal populations using limiting dilution 
assays from highly enriched PECAM-1+ fractions (Fig. 2.2a). In 50% enriched fractions, 
PECAM-1+ tumor cells were visible as large, flattened colonies that were distinct in appearance 
from spindle-shaped, PECAM-1− tumor cells (Supplementary Fig. 2.1b). These PECAM-
1+ tumor cells could be cleanly separated from their PECAM-1− counterparts using cloning rings 
or multiple rounds of immunomagnetic separation with PECAM-1 antibodies followed by 
limiting dilution assays. qPCR using clonally-derived populations revealed robust PECAM-
1 mRNA expression in clones A2 and A5 but not in clone A1 (Fig. 2.2b). No mRNAs were 
detected for VE-cadherin or Vegfr-2 in PECAM-1− or PECAM-1+ tumor cells. Tyr was expressed 
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by all melanoma cells but not mEC, as expected. Confocal microscopy revealed that PECAM-1 
was concentrated at the cell membrane in mEC but was diffusely localized at the membrane and 
throughout the cytoplasm in PECAM-1+ tumor cells (Supplementary Fig. 2.1c). Western blotting 
confirmed a migrating band at the expected size for murine PECAM-1 in PECAM-1+ clones 
(Fig. 2.2c). PECAM-1 was tyrosine phosphorylated in PECAM-1+ tumor cells suggesting it may 
have similar signaling abilities in both EC and tumor cells (Supplementary Fig. 2.1d). 
PECAM-1+ melanoma cells generate PECAM-1+ progeny 
We found that PECAM-1 expression in PECAM-1+ clones was stable in vitro and was 
not diminished by growth in different culture media (Supplementary Fig. 2.2a). However, cell-
surface PECAM-1 was reduced by > 50% when PECAM-1+ tumor cells were detached from 
tissue culture dishes using trypsin as opposed to accutase which does not affect PECAM-1 
surface expression (Supplementary Fig. 2.2b). Additionally, routine passaging of cells did not 
diminish PECAM-1 expression (Supplementary Fig. 2.2c). Interestingly, PECAM-1+ tumor cells 
displayed a slight growth delay in vitro and in vivo when engrafted into mice (Supplementary 
Fig. 2.2d). Long-term in vitro propagation of PECAM-1− and PECAM-1+ tumor cells revealed 
that PECAM-1+ tumor cells generally give rise to PECAM-1+ progeny and vice versa 
(Supplementary Fig. 2.2e). To determine the fate of PECAM-1− and PECAM-1+ tumor cells in 
vivo, we transduced PECAM-1+ and PECAM-1− tumor cells with GFP using lentivirus to 
generate PECAM-1+/GFP+ (clone A5) or PECAM-1−/GFP+ (clone A1) lines. We then injected 1.0 
× 106 tumor cells subcutaneously in wild type C57BL/6 mice. Flow cytometry of collagenase-
dispersed tumors revealed that, in general, PECAM-1+ tumor cells generate PECAM-1+ progeny 
whereas PECAM-1− tumor cells generate mostly PECAM-1− progeny (Supplementary Fig. 2.2f). 
When quantified by flow cytometry, PECAM-1− tumors generated a mixed population consisting 
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of ~ 2% PECAM-1+ progeny and ~ 98% PECAM-1− progeny. These results suggest that 
PECAM-1− and PECAM-1+ melanoma cells are stable subpopulations but may generate their 
counterparts at low frequencies with a tendency for PECAM-1− tumor cells to generate PECAM-
1+ progeny. Finally, karyotypes performed on PECAM-1+ and PECAM-1− clones showed that 
PECAM-1− tumor cells were more variable in chromosome counts with a median chromosome 
number of 70 whereas PECAM-1+ tumor cells had a median chromosome count of 64 
(Supplementary Fig. 2.3a, b). Both PECAM-1− and PECAM-1+ clones displayed similar marker 
chromosomes to those observed in previously published reports of the B16 cell line (Hu, Wang, 
& Hsu, 1987; Kendal, Wang, Hsu, & Frost, 1987). This result, in addition to the shared 
chromosomal aberrations between the two populations, suggests that the PECAM-1+ fraction 
may have persisted and been continuously generated at a low frequency within the B16F10 cell 
line for decades. 
In vitro vascular properties of PECAM+ melanoma 
To further characterize established PECAM-1+ clones, we carried out a microarray 
analysis using an Affymetrix mouse gene ST1.0 platform. A complete microarray dataset 
showing differentially expressed genes in PECAM-1− and PECAM-1+ tumor cells has been 
uploaded to the Gene Expression Omnibus (GEO). Notably, microarray analysis showed an 
enrichment of additional candidate genes associated with known vascular functions in PECAM-
1+ clones (A2, A3, A4, A5) compared to parental B16F10 tumor cells. These genes 
included Ephb4, Bmpr2, Pdgfa, Icam1 (CD54), Thbs1, Bmp1, Rbpj1, and Notch2 (Fig. 2.2d). 
Expression of these genes was confirmed by qPCR (Supplementary Fig. 2.4 and 
see Supplementary Table 2.1 for a complete list of PCR primer sets). 
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Because PECAM-1 is a cell adhesion molecule known to mediate in vitro tube formation 
of bona fide EC, we assessed whether PECAM-1+ melanoma cells might also undergo in vitro 
tube formation (Cao et al., 2002; DeLisser et al., 1997). PECAM-1+ tumor cells displayed a 4–5 
fold increase in branching tube-like networks compared to their PECAM-1− counterparts. 
PECAM-1− tumor cells only formed occasional tube-like structures which were not stable in 
culture. Tube like-structures in PECAM-1+ tumor cells could be inhibited by ~ 50% using a 
PECAM-1 blocking antibody indicating a functional role for PECAM-1 in this assay (Fig. 2.2e) 
(DeLisser et al., 2010). Gain of function experiments showed that PECAM-1 over-expression 
(OE) in PECAM-1− tumor cells (clone A1) stimulated in vitro tube formation ~ 4-fold whereas 
PECAM-1 shRNA in PECAM-1+ tumors cells (clone A5) diminished tube formation by ~ 50% 
(Fig. 2.2f, g, h, i). These results suggest that PECAM-1 is a marker of a unique subpopulation of 
B16F10 tumor cells and it plays a functional role in the establishment and stability of in vitro 
tube-like networks. 
PECAM-1+ tumor cells exist in spontaneous murine melanoma 
Next, we turned to the ΔBraf/Pten−/− genetically-engineered mouse model of melanoma 
to assess whether PECAM-1+ tumor cells were present in spontaneous tumors (Fig. 2.3a) 
(Dankort et al., 2009). First, we measured PECAM-1mRNA expression using qPCR in two cell 
lines recently derived from tumors in ΔBraf/Pten−/− mice (Hanna et al., 2013). The results 
showed that PECAM-1 mRNA levels were above the zero transcript threshold we established 
using a known PECAM-1− clone derived from B16F10 (clone A1) (Fig. 2.3b). These results 
suggested that, similar to B16F10, a minor subpopulation of PECAM-1+ tumor cells might be 
present within ΔBraf/Pten−/− tumor cells. To address this possibility, we used PECAM-1-
mediated immunomagnetic enrichment in PBT2460 tumor cells and found that after six 
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enrichment steps, about 15% of the population expressed PECAM-1 on the cell surface by flow 
cytometry. After two additional enrichment steps, about 98% of the population expressed 
PECAM-1 (Fig. 2.3c). qPCR confirmed an ~ 100-fold increase in PECAM-1 mRNA in the 
enriched fraction when compared to the un-enriched parental population but VE-
cadherin and Vegfr-2 were absent from both populations (Fig. 2.3d). Notably, these PECAM-
1+ cells derived from ΔBraf/Pten−/− tumors were not identical to those obtained from B16F10; 
namely, unlike PECAM-1+ cells from B16F10 melanoma, they did not express ICAM1 protein 
or mRNA by qPCR (Supplementary Fig. 2.5a, b). 
Using the enriched PECAM-1+ fraction from ΔBraf/Pten−/− tumors, we generated single-
cell clones by limiting dilution assays. Similar to PECAM-1+ tumor cells derived from B16F10, 
single cell clones derived from ΔBraf/Pten−/− tumors maintained PECAM-1 expression in culture 
that was detectable on the cell surface by flow cytometry (Fig. 2.3e). Furthermore, clonally-
derived PECAM-1+ tumor cells from ΔBraf/Pten−/− tumors showed a five-fold increase in the 
formation of vascular-like networks in vitro compared to their PECAM-1− counterparts (Fig. 
2.3f). As with B16F10-derived PECAM-1+ tumor cells, these tube-like structures were stable 
over time but could be diminished by ~ 50% using a PECAM-1 neutralizing antibody (Fig. 
2.3g, Supplementary Movie 1). 
PECAM-1+ melanoma cells integrate into vessel lumens in vivo 
To assess whether PECAM-1+ melanoma cells generated vessel-like structures in vivo, 
we engrafted unlabeled, clonally-derived PECAM-1+ (clone A5) and PECAM-1− (clone A1) 
melanoma cells under the skin of C57BL6/J mice. We then stained cryosections with antibodies 
against PECAM-1 and the melanoma marker S100B (Eyles et al., 2010). Strikingly, in PECAM-
1+ tumors, we found intra-tumoral holes and channels lined by PECAM-1+/S100B+ tumor cells 
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(Fig. 2.4a). These channels appeared to be formed entirely by PECAM-1+/S100B+ tumor cells 
(top row) or were formed in collaboration with PECAM-1+/S100B+ tumor cells and host 
endothelium (middle row). In contrast, PECAM-1− tumors were characterized by host-derived 
PECAM-1+ vasculature juxtaposed to S100B+ tumor cells (bottom row). Next, we used GFP-
labeled PECAM-1+ and PECAM-1− clonally-derived populations from B16F10 to further assess 
the localization of PECAM-1− and PECAM-1+ tumor cells in vivo by immunohistochemistry. 
Similar to the results above, in PECAM-1+ tumors, co-staining using PECAM-1 and GFP 
antibodies revealed large openings, intratumoral channels, and vascular-like structures that 
incorporated GFP+ tumor cells within their lumens (Fig. 2.4b, first row). In contrast, host-derived 
PECAM-1+ vascular EC were mainly peripheral to GFP+ tumor cells in PECAM-1− tumors (Fig. 
2.4b, second row). We then determined whether PECAM-1+ tumor cells were also incorporated 
into VE-cadherin+ vascular lumens. Similar to the staining pattern for PECAM-1 above, we 
found that PECAM-1+ tumor cells formed mosaic vascular structures and were incorporated 
within occasional VE-cadherin+ lumens (Fig. 2.4b, third row). In contrast, PECAM-1− 
counterpart tumor cells were localized to the margins of host-derived VE-cadherin+ blood vessels 
(Fig. 2.4b, fourth row). Taken together, these results suggest that PECAM-1+ melanoma cells 
have vascular-like properties including the ability to spontaneously organize into tube-like 
structures in vitro and incorporate into vascular lumens in vivo. 
PECAM-1+ melanoma form perfused vascular structures in mice 
To determine whether PECAM-1+ tumor cells were in direct contact with the host 
circulation, we examined paraffin-embedded tumor sections stained with GFP antibodies 
visualized using 3,3′ diaminobenzidine (DAB). The results showed numerous channels or 
“lumens” that were comprised of GFP+ tumor cells in direct contact with erythrocytes (Fig. 2.5a). 
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H & E stained sections showed large dilated vessels, hemorrhage, and blood-filled channels in 
PECAM-1+ tumors versus their PECAM-1− counterparts (Fig. 2.5b). When quantified using the 
ImageJ software package, the mean hemorrhage area for PECAM-1− tumors was 46.7 AU +/− 
1.3 and 88.3 AU +/− 23.0 for PECAM-1+ tumors (Fig. 2.5b, lower panel). In support of a 
PECAM-1-dependent form of VM in this model, this increase in hemorrhage area was 
diminished when PECAM-1+ tumors were engrafted in PECAM-1 KO mice (Supplementary Fig. 
2.6a, b, c). 
Next, we carried out 3D acoustic angiography and dynamic contrast-enhanced perfusion 
imaging using lipid-encapsulated micro-bubble contrast agents to measure real-time tumor 
perfusion and vascular structure in PECAM-1− and PECAM-1+ tumors (Fig. 2.5c, left) (Gessner, 
Aylward, & Dayton, 2012). Dual-frequency, 3D acoustic angiography revealed mean volumetric 
vascular density values of 47.9 +/− 2.9 for PECAM-1− tumors, whereas PECAM-1+ tumors had 
mean volumetric vascular density values of 72.3 +/− 5.5 (Fig. 2.5c, middle). The sample means 
were statistically significant when analyzed using a two tailed t-test. We observed that the 
acoustic angiography images showed the presence of greater sub-resolution contrast in PECAM-
1+compared to PECAM-1− tumors. This sub-resolution contrast signal likely emanates from 
pooling blood, which could correspond with the larger hemorrhage areas observed in PECAM-
1+ tumors. Additionally, destruction-reperfusion images acquired longitudinally were used to 
compute the area-normalized relative blood volume (normalized RBV) analyzed using a linear 
mixed effects model in R. The area-normalized RBV regression intercept was 3.46 +/− 2.95 units 
for PECAM-1− tumors and 15.60 +/− 4.76 units for PECAM-1+ tumors which was statistically 
significant (Fig. 2.5c, right). Overall, these results demonstrate that the normalized RBV of 
PECAM-1+ tumors was an average of 4.5 times higher than that of PECAM-1− tumors. 
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To determine whether PECAM-1+ tumor cells were in contact with the circulation, we 
injected Texas Red-labeled high molecular weight Dextran (TR-Dextran) by way of the tail vein 
in mice bearing PECAM-1−/GFP+ or PECAM-1+/GFP+ tumors (Lin et al., 2006). GFP+ tumor 
cells in direct contact with TR-Dextran were then analyzed using confocal microscopy (Fig. 
2.5d). After analyzing multiple sections from 3–4 mice/group, we found a six-fold increase in 
PECAM-1+ tumor cells in contact with TR-Dextran when compared to their PECAM-
1− counterparts. These results were confirmed in an additional PECAM-1+ clone (clone A2) 
(Supplementary Fig. 2.7a, b, Supplementary Movies 2, 3). Finally, we carried out transmission 
electron microscopy (TEM) of engrafted PECAM-1− and PECAM-1+ tumors. The ultrastructure 
of vessels in these tumors showed melanoma cells (identified by the presence of melanosomes, a 
unique feature of melanocytes and melanoma cells) in direct contact with the basal lamina of 
erythrocyte-containing vessels in PECAM-1+ tumors, but this contact was rarely seen in 
PECAM-1− tumors (Supplementary Fig. 2.8). Thus, these results suggest that PECAM-1+ tumor 
cells organize into primitive vascular channels that may be affiliated with the host circulation and 
perfused with blood. 
AP-2α is reduced in PECAM-1+ tumor cells and represses PECAM-1 
Next, we asked how PECAM-1 expression was transcriptionally-regulated in PECAM-
1+ tumor cells. Notably, we did not find evidence for epigenetic regulation of PECAM-
1 expression in B16F10 because neither the DNA methyltransferase inhibitor 5-azacytidine nor 
the pan-HDAC inhibitor TSA could induce PECAM-1 mRNA (Supplementary Fig. 2.9a). 
However, PECAM-1 is known to be regulated by the transcription factor GATA2 and additional 
binding sites in the PECAM-1 promoter for SP1, ETS, and AP-2α are also reported (Gumina, 
Kirschbaum, Piotrowski, & Newman, 1997). We scanned the PECAM-1 promoter and used 
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semi-quantitative RT-PCR to measure the expression of these candidate transcription factors in 
PECAM-1− and PECAM-1+ clones. The results showed that unsorted B16F10 melanoma and 
clonally-derived PECAM-1− or PECAM-1+ tumor cells either did not express or expressed 
similar levels of most of these transcription factors, including Ets (Fig. 2.6a). On the other 
hand, Ap-2α expression was strikingly diminished in PECAM-1+ tumor cells and mEC but was 
expressed in unsorted B16F10 cells and PECAM-1− tumor cells. Ap-2α expression was similar in 
parental B16F0, the low-metastatic B16 clone B16F1, B16F10, and two independent PECAM-
1− clones (Supplementary Fig. 2.9b). Expression of the well-characterized melanoma markers 
dopachrome tautomerase (Dct) and micropthalmia-associated transcription factor (Mitf-m) were 
also similar in these same cell lines at the mRNA and protein levels (Supplementary Fig. 2.9b, 
c). Interestingly, PECAM-1+ clones consistently produced more pigmented cells in vitro and 
highly pigmented tumors in vivo despite expressing similar levels of Tyr and Dct compared to 
PECAM-1− counterparts (Supplementary Fig. 2.9d, e). 
Because AP-2α levels were inversely correlated with PECAM-1, we hypothesized that 
AP-2α might function as a transcriptional repressor of PECAM-1. We used chromatin 
immunoprecipitation (ChIP) to confirm that AP-2α occupied the PECAM-1 promoter in B16F10 
tumor cells. Immunoprecipitation with an AP-2α antibody followed by PCR using two primer 
sets unique to the mouse PECAM-1 promoter revealed amplified fragments of the predicted sizes 
(Fig. 2.6b). Furthermore, PECAM-1− tumor cells transfected with Ap-2α siRNA revealed up-
regulation of PECAM-1 mRNA and protein expression, which was accompanied by a four-fold 
increase in tube formation in Matrigel (Fig. 2.6c, d). On the other hand, stable lentiviral re-
expression of Ap-2α into PECAM-1+ tumor cells resulted in down-regulation of PECAM-
1 mRNA and protein expression, and a 6-fold reduction in tube formation (Fig. 2.6e, 
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f, Supplementary Movie 4). These results suggest that AP-2α may repress PECAM-1 expression 
and that diminished expression of AP-2α in PECAM-1+ B16F10 cells accompanies their ability 
to form vascular like structures in vitro. 
PECAM-1+ tumor cells are enriched after anti-VEGF therapy 
Because PECAM-1+ tumor cells do not express VEGFR-2, but engage in VM, we 
hypothesized they might form VEGF-independent intratumoral channels in mice. First, we 
subjected mice bearing B16F10-GFP tumors to MCR84, a neutralizing antibody raised against 
VEGF-A, and then harvested tumors once they become refractory to further treatment (Fig. 2.7a) 
(Roland et al., 2009; Sullivan et al., 2010). MCR84-treated mice demonstrated a characteristic 
delay in tumor growth, followed by tumor regrowth that was resistant to further VEGF inhibition 
(Fig. 2.7b). We then used flow cytometry to measure the proportion of GFP+/PECAM-1+ tumor 
cells in size-matched tumors. We found that in size-matched, MCR84-resistant tumors, the 
number of PECAM-1+ tumor cells was enriched ~ 6 fold whereas PECAM-1− tumor cells and 
bona fide EC were marginally reduced (Fig. 2.7c, d). To examine the specific role of PECAM-
1+ tumor cells in tumor responses to anti-angiogenic therapy, we engrafted GFP-labeled clonally-
derived populations of either PECAM-1+ or PECAM-1− tumor cells into C57BL6/J mice. Mice 
were then treated with MCR84 as described above. We found that PECAM-1− tumors 
demonstrated an expected delay in tumor growth and reduction in tumor volume (~ two-fold 
decrease in tumor volume at day 15) when challenged with MCR84. On the other hand, 
PECAM-1+ tumors showed no appreciable growth inhibition compared to controls (Fig. 2.7e). H 
& E and GFP-stained tissue sections revealed striking differences in blood vessel morphology 
and numerous blood-filled “channels” encapsulated by GFP+ tumor cells in the PECAM-
1+ tumors challenged with MCR84 (Fig. 2.7f). Taken together, VEGF blockade induces 
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expansion of a minor subpopulation of PECAM-1+melanoma cells; furthermore, PECAM-
1+ melanoma cells form tumors that do not respond to VEGF inhibition and they generate 
aberrant vascular-like structures following challenge with VEGF blocking antibodies. 
Human melanoma contains a PECAM-1+ subpopulation 
We examined PECAM-1 expression from microarray data generated from > 40 human 
melanoma cell lines and normal human melanocytes (Carson et al., 2012). From these data, we 
identified approximately 10 cell lines which fell above a threshold (~ 1.5 adjusted mean 
fluorescence values from microarray data) established using normal human melanocytes which 
do not express PECAM-1 (Fig. 2.8a). A list of normal melanocytes and melanoma cells along 
with the raw fluorescence values from the microarray are shown in Supplementary Table 2.2. We 
began by culturing some of the highest PECAM-1-expressing cell lines and measuring PECAM-
1 mRNA levels by quantitative RT-PCR. The results showed that, as predicted from the 
microarray analysis, PECAM-1 mRNA was detected in the WM2664, MEL505, RPMI7951, 
WM1158, and SBCl2 cell lines albeit at vey low levels compared to human EC (hEC) (Fig. 
2.8b). No PECAM-1 transcripts were detected in normal melanocytes, RPMI8332, or 
SKMEL119 which all fell below the established threshold on the microarray. On the other 
hand, VE-CADHERIN mRNA, which is expressed in some uveal forms of melanoma that engage 
in vasculogenic mimicry, was not detected in most cell lines but was found at very low levels in 
WM1158 cells (Hendrix et al., 2001). Using flow cytometry, we could detect a minor shift in 
PECAM-1 fluorescence in RPMI7951 (3.3%) and WM1158 cells (1.6%) but a much larger shift 
in SBCl2 cells (50%). No PECAM-1 surface expression was detected in normal melanocytes 
(NHM7) or in RPMI8332, as expected (Fig. 2.8c). Similar to the PECAM-1+ fractions derived 
from murine B16F10 and ΔBraf/Pten−/− cells, SBCl2 melanoma cells formed robust and stable 
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vessel-like networks in vitro which were inhibited by PECAM-1 neutralizing antibodies (Fig. 
2.8d, Supplementary Movie 5). 
Because SBCl2 expressed detectable PECAM-1 levels by flow cytometry, we engrafted 
this cell line subcutaneously in NOD-SCID-Il2γ (NSG) mice. We then stained primary, paraffin-
embedded SBCl2 tumors with PECAM-1 antibodies that were verified to be human specific 
using western blotting and immunohistochemistry (Supplementary Fig. 2.10a, b). While the 
majority of PECAM-1+ tumor cells detected with human antibodies appeared randomly scattered 
throughout the tumor, occasional PECAM-1+ “lumens” were also visible (Fig. 2.8e). Overall, 
PECAM-1+ tumor cells were found at the luminal and abluminal surface of vascular structures 
(white arrowheads), and were detected in all SBCl2 tumors examined, and were present at an 
average density of ~ 5 vessel-like structures per mm2 when normalized to tumor size for each 
tissue section (Fig. 2.8e, far right). Thus, similar to mouse melanoma, a subpopulation of some 
human melanoma cells express PECAM-1 and engage in the formation of vascular-like 
structures in vitro and in vivo. 
Materials and Methods 
Mice  
For studies using the B16F10 melanoma cell lines, female C57BL6/J mice were used 
(Jackson Laboratories, Bar Harbor, ME). Mice were injected with tumor cells at 7-8 weeks of 
age. For engraftment of human melanoma cells, we used female NSG mice (7-8 weeks of age) 
provided by the mouse phase I unit at UNC. C57BL/6-Tg (CAG-EGFP)1Osb/J mice were 
purchased from Jackson Laboratories, (Bar Harbor ME). PECAM-1 knockout mice were kindly 
provided by Dr. E. Tzima (UNC Chapel Hill), and tumor cells were engrafted in female mice at 
7-8 weeks of age. All mouse experiments were carried out in accordance with protocols 
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approved by the Institutional Animal Care and Use Committee at the University of North 
Carolina at Chapel Hill.  
Cell lines and media  
B16F0, B16F1, B16F10 (ATCC), ΔBraf/Pten-/- (derived from B6.Cg-
Braftm1MmcmPtentm1HwuTg(Tyr- cre/ERT2)13Bos/BosJ mice (UNC-Chapel Hill Mouse Phase 1 Unit)) cell 
lines PBT2460 and PBT2130 (Drs. W. Kim and J. Bear, UNC-Chapel Hill), and human 
melanoma cell lines WM1158, SBCl2, Sk-Mel-119, Sk-Mel-173, and WM2664 (Dr. J. Shields, 
UNC-Chapel Hill) were maintained in DMEM with 4.5 g/mL D-Glucose and 10% FBS. Human 
melanoma cell lines RPMI7951, RPMI8322, and Mel505 (Dr. J Shields, UNC-Chapel Hill) were 
maintained in RPMI with 10% FBS. The normal human melanocyte line NHM7 (Dr. J Shields, 
UNC-Chapel Hill) was maintained in Media 254 (Gibco) supplemented with HGMS (Gibco). EC 
were maintained in Endothelial Cell Media (EC-Media), composed of DMEM with 1g/L 
glucose, 5 μg/L bFGF, 10 μg/L VEGF, 100 mg/L heparin, antibiotics, and 10% NuSerum IV 
(BD).  
Antibodies  
For a complete list of antibodies and dilutions used, please refer to Supplementary Table 
3.  
Western blotting  
Whole cell lysates were prepared in radioimmunoprecipitation assay buffer (RIPA, 
Boston BioProducts), separated by SDS-PAGE at 100V using a Bio-Rad 4-20% TGX gel (Bio-
Rad), blocked with 5% Milk-TBS-T for standard western blotting, 5% BSA for phospo-
VEGFR2 blotting , and probed with antibodies overnight at 4°C. Peroxidase-conjugated 
secondary antibodies were incubated at RT for 1 hour, and bands were exposed with Western 
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Lightning (PerkinElmer). Blots were imaged on a Fluorchem M (ProteinSimple). All antibodies 
and dilutions are presented in Supplementary Table 3.  
Chromatin immunoprecipitation (ChIP)  
ChIP experiments were performed using the ChIPit Express Kit (Active Motif) according 
to the manufacturer’s instructions. 2 μg anti-AP-2α antibodies were used for 
immunoprecipitation and bound DNA was analyzed using two primer sets designed against the 
mouse PECAM-1 promoter  for sequences see Supplementary Table 2.1).  
siRNA Knockdown  
Cells were plated at 2.0 x105 cells/well in 6-well plates. siRNA SmartPools (Dharmacon) 
targeting Ap-2α (M-062788-01-0005), PECAM-1 (TRC RMM4534-EG18613), or non-targeting 
controls (D-001206- 13-05) were added to plates the next day according to the manufacturer’s 
instructions at a concentration of 100 nM. Cells were allowed to grow for 48 hours before 
harvesting.  
Isolation of PECAM-1+ tumor cells  
Tumors were harvested and prepared for cell isolation as previously described by us 
(Dudley et al., 2008; 2010). In brief, tumors were minced in cold DMEM with 1 g/L glucose. 
Tumors were further digested using a mechanical tissue homogenizer (Miltenyi). Samples were 
incubated at 37°C with 5 ml Collagenase T2 (2 mg/ml, Worthington), 1 mL neutral buffered 
protease (2.5 U/ml, Worthington), and 75 μL deoxyribonuclease (1 mg/mL, Worthington) for 75 
minutes. Red blood cells were lysed with 1X Pharmlyse B (BD PharMingen). Cells were 
suspended in FACS Buffer (degassed phosphate-buffered saline containing 2 mM EDTA and 
0.5% BSA), Fc receptors were blocked with Fc Block (Miltenyi), and 10 μg PE-conjugated anti-
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PECAM-1 antibodies were added for 20 minutes. Cells were washed and resuspended with anti-
PE magnetic beads (Miltenyi) for 15 minutes. Cells were then washed and passed over a 
magnetic column, washed, and then eluted. Eluted cells were washed and plated in EC-Media. 
Cells were grown for several weeks, and the isolation was repeated until cultures reached ~ 99% 
PECAM-1 positivity, at which point single cell clones were made by limiting dilutions.  
Tumor dissociation and flow cytometry  
Single cell suspensions were prepared either from whole tumors as described above or 
from detached cell cultures as previously described by us (Dudley et al., 2010). Briefly, cells 
were washed with PBS and detached using accutase (Sigma) and then labeled with fluorophore-
tagged antibodies. Cells were then washed and fixed in FACS buffer containing 1% 
paraformaldehyde. Cells were analyzed by flow cytometry using an Accuri C6 flow cytometer 
running BD Accuri CFlow Plus Analysis software. Samples were then analyzed using the FloJo 
software package (version 10).  
Immunohistochemistry  
Tumors were harvested and fixed in 4% paraformaldehyde overnight at 4°C. Samples 
were then cryoprotected in 30% sucrose overnight. Samples were frozen in OCT and cut into 7 
μm sections. Slides were fixed in methanol for 20 minutes, and washed in PBS. Sections were 
blocked in 5% BSA with species-specific serum (5%) for one hour, and antibodies were added in 
blocking buffer. All antibodies and dilutions are described in Supplementary Table 3. Slides 
were incubated overnight at 4°C. Slides were washed and secondary antibodies were added for 
one hour at room temperature. Slides were counterstained with Vectashield Hard-set Mounting 
Medium with DAPI (Vector Labs). Sections were analyzed on a Leica DM-IRB inverted 
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microscope or a Zeiss 710 laser scanning confocal microscope. Images were globally adjusted 
using ImageJ analysis software (http://rsb.info.nih.gov/ij) to enhance contrast and sharpness.  
Acoustic angiography and perfusion imaging  
Two methods of contrast enhanced ultrasonography were employed to quantify perfusion 
in PECAM-1+ and PECAM-1- tumors in vivo. Additionally, non-contrast ultrasound provided 
reference anatomical information and tumor volume. The lipid encapsulated microbubble 
contrast agents were prepared as previously described and injected intravenously through a tail-
vein catheter (Streeter, Gessner, Miles, & Dayton, 2010). Destruction-reperfusion imaging was 
performed using a Vevo 2100 ultrasound system (VisualSonics, Toronto, Ontario, Canada), 
similar to methods used as described previously (Kogan et al., 2011). Dynamic contrast 
enhanced perfusion imaging sequences were used to compute relative blood volumes (VevoCQ- 
Advanced Contrast Quantification Software Analysis Tool for the Vevo 2100. VisualSonics. 
Toronto, Canada, © Bracco Suisse S.A. 2010). Data were normalized by tumor cross-sectional 
areas as defined by regions of interest (ROIs) drawn manually. Acoustic angiography utilizes a 
prototype dual- frequency transducer, with a low frequency element to transmit at 4 MHz, 
exciting microbubbles to produce broadband, superharmonic echoes (at a mechanical index of 
0.6). The confocal high frequency element (30 MHz) is used to receive the microbubble 
response, thus avoiding tissue signal and producing high-contrast, high resolution images of the 
tumor microvasculature without tissue background, in 3 dimensions (Gessner et al., 2012). 
Acoustic angiography is acquired near simultaneously with b-mode soft tissue imaging, which 
provides anatomical reference. These images were used to compute the volumetric vascular 
density of the tumors using the following procedure in MATLAB (The MathWorks Inc., Natick, 
MA). First, ROIs were drawn manually to define tumor boundaries based on the b-mode images. 
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Then, the ROIs were applied to mask the tumor volume in the acoustic angiography images. 
Finally, the vascular volume was computed by applying an intensity threshold cutoff, to segment 
the image into vascular and nonvascular regions. The volumetric vascular density is the ratio of 
the number of voxels classified as vascular volume over the total number of voxels in the tumor 
ROI. Statistical analysis was carried out using R (http://www.R-project.org).  
Transmission electron microscopy  
PECAM-1+ or PECAM-1- tumors were grown as described above. Tissues were 
harvested, fixed in 2.5% glutaraldehyde/2% PFA in 0.15M sodium phosphate buffer. Samples 
were post-fixed for 1 hour in 1% osmium tetroxide in 0.15M sodium phosphate buffer, 
dehydrated with a graded series of ethanol washes, treated with propylene oxide and embedded 
in PolyBed 812 epoxy resin (Polysciences, Warrington, PA). Ultrathin sections (70-80 nm) were 
cut and mounted on copper grids and stained with 4% aqueous uranyl acetate and Reynolds’ lead 
citrate. Sections were mounted to copper grids, OsO4 was used to stain the tissues and sections 
were imaged on a Zeiss Leo EM910 TEM.  
Lentiviral constructs and transduction  
All recombinant DNA work was carried out under approval of the Environmental Health 
Safety Division of UNC-Chapel Hill. Lentiviral expression plasmids were created by E. 
Campeau and obtained from Addgene: pLenti CMV-GFP-DEST (736-1, Addgene plasmid 
19732), pLenti CMV/TO GFP-Zeo DEST (719-1, Addgene 17431). Packaging plasmids psPax2 
and pMD2.6 were created by Didier Trono (Addgene plasmids 12259 and 12260). Mouse ORF-
eome constructs were acquired from the ATCC I.M.A.G.E Consortium, then cloned into pDONR 
221  (Invitrogen) Gateway donor vectors using Clonase BP (Invitrogen). Cloned pDONR 221 
vectors were sub-cloned into lentiviral expression vectors by Clonase LR reaction (Invitrogen). 
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Lentiviral backbones were transfected with 1.5 μg packaging plasmids psPAX2 and pMDG2 
with 15 μl Lipofectamine 2000 in 6-well plates into HEK293T cells. Viral particles were 
harvested at 24 and 48 hours post transfection. Viral particles were used to infect target cells 
with 10 μg/mL Polybrene in antibiotic-free media.  
Tumor studies in mice  
B16F10 melanoma cells were grown in appropriate culture medium, detached and 
resuspended in HBSS (Gibco). 1.0 x 106 tumor cells were injected subcutaneously in the right 
shoulder of C57BL6/J mice. Tumors were allowed to grow to 1 cm3 and were measured daily 
with calipers. For MCR84 studies, mice were treated with 25 mg/kg/day MCR84 or isotype 
control antibodies as previously described (Roland et al., 2009; Sullivan et al., 2010). Tumor 
sizes were measured with calipers each day. At the end of the experiment, mice were euthanized 
and tumors were harvested and weighed.  
Microarray analysis  
RNA was harvested from cell lines and run on a Mouse Gene ST1.0 Chip (Affymetrix). 
Heat maps were generated using the Gene-E software package, version 2.1.134. 
(http://www.broadinstitute.org/cancer/software/GENE-E/). Microarray dataset is available at the 
Gene Expression Omnibus, accession number: GSE59564.  
Polymerase chain reaction (PCR)  
Primers were designed using Invitrogen Primer Perfect Design Software. End-point PCR 
was completed using a standard PCR kit (NEB). RT-qPCR was completed with Maxima SYBR 
Green (ThermoFisher) on an Applied Biosystems Step One Plus analyzer. All qPCR experiments 
were run in triplicate and data are presented as the average with the standard error of the mean 
(s.e.m.). Primer sequences used are presented in Supplementary Table 1.1.  
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Tumor hemorrhage quantification  
H & E stained sections were imaged using polarized light microscopy which caused red 
blood cells (RBC) to fluoresce. Images were subsequently converted to a binary image using 
ImageJ software. The images were then thresholded to only show RBC and the “count particles” 
tool was used to analyze RBC content. The first 500 observations were binned and plotted.  
In vitro tube-forming assays  
Briefly, 50 μL Matrigel (BD) was plated in 96-well culture dishes and allowed to 
polymerize at 37°C for 30 minutes. Next, 2.5 x 104 cells/well were plated on the Matrigel layer 
and grown for 16 hours. Randomized fields were captured using a DM-IRB inverted microscope 
and tubes were quantified from each image. Data are presented as the average number of tubes 
per field +/- SEM from multiple fields. For live imaging experiments Matrigel was plated in 24-
well plates, and 5 x 104 cells/well were seeded on top of the layer. Tube formation was imaged 
on a Leica IX70 microscope outfitted with an environmental chamber. Data were compiled using 
ImageJ Analysis Software. Brightfield images were converted to eight-bit black and white and 
the “find edges” command was used to identify cells. Images were enhanced using sharpen tools 
and pseudocolored for video analysis.  
Dextran perfusion  
Dextran perfusion was carried out according to previously-published methods (Lin et al., 
2006). GFP labeled tumor cells were injected subcutaneously as described. Once tumors reached 
1 cm3, mice were injected with 100 μL, 70 kD-Texas Red Dextran  (Life Technologies) via the 
tail vein and sacrificed three minutes post-injection. Tumors were prepared for 
immunohistochemistry as described and imaged with a Zeiss LSM700 scanning laser confocal 
microscope. Tumor-cell affiliated dextran was quantified by identifying GFP+ cells abutting on 
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dextran-lined channels in tumors and are presented as average tumor cells integrated within 
lumens per field.  
XTT Assay  
XTT Assay Kit (ATCC) was used to measure growth of cells. 5,000 cells were plated in 
triplicate in a 96 well plate. XTT reagent was prepared per manufacturers recommendations, 
added to wells, and absorbance at 475 nm was measured after 4 hours.  
5-azacytadine (5-aza) and trichostatin A (TSA) treatment  
5-Aza (stock: 819mM) or TSA (stock: 6.6mM) were diluted as indicated and added to 
media. Cells were harvested seven days later and RNA was purified for semi quantitative RT-
PCR analysis.  
Karyotypes  
Cells were treated with 0.1 mg ml 1 colcemid (Irvine Scientific) for 3 h to accumulate 
cells in metaphase. Cells were then treated with hypotonic 0.075 M KCl for 25 min at 37°C and 
fixed in 3:1 methanol/acetic acid. Air-dried slides were stained for G-band analysis and at least 
20 metaphase cells were counted for each cell line by the Brigham and Women’s Hospital 
CytoGenomics Core Laboratory, Boston, MA, USA.  
Statistical analysis  
Statistical power for mouse experiments was calculated using Biomath 
(biomath.info/power). All samples sizes were equal to or greater than recommended minimum 
group size. All measurements in mouse studies were done with the assistance of at least one 
blinded researcher for recording and confirmation. Statistical analysis was carried out using the 
Graphpad Prism 5.0f statistical analysis package unless otherwise noted. Figure legends list 
specific n and P values. Data are presented as mean±standard error of the mean (s.e.m.).  
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Figure 2.1. Identification, isolation, and characterization of PECAM-1+ tumor cells from 
B16F10 melanoma.  
(a) PECAM-1 antibodies coupled to immunomagnetic beads were used to enrich PECAM-1+ 
tumor cells from collagenase-digested B16F10 tumors. (b) The enriched cells (eluate) are ~ 99% 
PECAM-1+ by flow cytometry. (c) Purity of the cells was further confirmed by semi-quantitative 
RT-PCR. The PECAM-1+ fraction from B16F10 expresses PECAM-1 and Tyr, but not VE-
cadherin. (d) Retrieval of PECAM-1+/GFP+ cells from GFP tumors engrafted in WT hosts and 
PECAM-1+/GFP- cells engrafted in GFP hosts. Following immunomagnetic separation with 
PECAM-1 antibodies, increasing amounts of cDNA template were analyzed by semi-quantitative 
RT-PCR, indicated by the wedge. (e) Detection of PECAM-1+/GFP+ tumor cells in vivo after 
injecting B16F10-GFP tumor cells into WT hosts. CD45+ hematopoietic cells were excluded by 
out-gating. The upper right quadrant are PECAM-1+ tumor cells which comprise ~ 0.1% of each 
tumor. (f) The percentage of PECAM-1+/GFP+ tumor cells are shown for two time points when 
tumors were different sizes, n=3 mice/group. (error bars = s.e.m) 
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Figure 2.2. PECAM-1+ clonally-derived populations from B16F10 melanoma display 
vascular characteristics and form PECAM-1-dependent tube-like structures.  
(a) Strategy for preparation of PECAM-1+ clonal populations from B16F10 melanoma using 
limiting dilutions of partially-enriched cellular fractions. (b) Characterization of PECAM-1- and 
PECAM-1+ clonal populations using qPCR. (c) Western blotting for PECAM-1 using whole cell 
extracts from the indicated cell type. PECAM-1 migrates at the expected size of ~ 130 kDa. 
Blots were stripped and re-probed with β-actin antibodies to show equal loading. (d) Microarray 
analysis of parental B16F10 and PECAM-1+ clonal populations derived from B16F10. Only 
known vascular or angiogenesis-related genes shown to be up-regulated in PECAM-1+ clones are 
shown. (e) Images from tube-forming assay in Matrigel comparing a PECAM-1- and PECAM-1+ 
clone. Tube-like structures in high power fields were quantified and plotted. Sample means were 
statistically significant as determined by a student’s t-test (p<0.02, n = 6 wells per condition). (f) 
qPCR analysis of PECAM-1 expression in PECAM-1- melanoma cells (clone A1) following 
ectopic PECAM-1 expression. (g) Images of control-transfected cells and PECAM-1 over- 
expressing cells (OE) are shown after a 16-hour tube formation assay and quantified at right. 
Means are statistically significant as determined by a student’s t-test (p<0.001, n = 6-7 wells per 
condition) (h) qPCR analysis of PECAM-1 expression in PECAM-1+ melanoma cells (clone A5) 
following shRNA knockdown. (i) Images of empty-vector transfected and PECAM-1 shRNA-
transfected cells are shown after a 16-hour tube formation assay and quantified at right. Means 
are statistically significant as determined by a student’s t-test (p<0.001, n = 7-8 wells per 
condition). (scale bars = 100 μm, error bars = s.e.m.)  
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Figure 2.3. PECAM-1+/VEGFR-2- tumor cells exist in a genetically engineered mouse 
model of melanoma and they form vascular-like networks in Matrigel.  
(a) Examples of tumors from ΔBraf/Pten-/- mice. (b) qPCR analysis of PECAM-1 expression in 
PECAM-1- and PECAM-1+ B16F10 clonal populations and two additional unsorted cell lines 
derived from dispersed tumors from ΔBraf/Pten-/-mice. mEC are a positive control for PECAM-1 
expression. (c) Flow cytometry analysis of unsorted (parental) PBT2460 cells shows ~ 3% 
positivity for PECAM-1. After six rounds of PECAM-1 selection, this fraction increases to ~ 
15% and after eight rounds to ~ 98%. (d) qPCR analysis of the parental PBT2460 population 
versus the 8X-enriched fraction. Basal PECAM-1 expression is ~ 100-fold higher in the 8X-
enriched fraction compared to unsorted PBT2460 cells, while neither population expresses VE-
cadherin or Vegfr-2. (e) Using the 8X enriched fraction, single cell clones were prepared by 
limiting dilution assays and then analyzed by flow cytometry for PECAM-1 expression. (f) 
Clonally-derived PECAM-1+ PBT2460 cells show an ~ 5-fold increase in tube formation as 
compared to PECAM-1- cells. Sample means were statistically significant as determined by a 
student’s t-test (p<0.01). (g) Time-lapse images of tube formation assay using clonally-derived 
PECAM-1+ PBT2460 cells incubated with either a non-specific IgG (top row) or PECAM-1-
blocking antibody (bottom row). Elapsed time is shown in hours. (h) PECAM-1 blocking 
antibodies reduce tube formation by ~ 50% in PECAM-1+ PBT2460 cells. (scale bars = 100 μm, 
error bars = s.e.m.) 
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Figure 2.4. PECAM-1+ melanoma cells integrate within vessel lumens in vivo. 
(a) Engraftment of unlabeled PECAM-1- (clone A1) and PECAM-1+ (clone A5) tumor cells in 
C57BL6/J mice. Tumors were implanted subcutaneously and then harvested ~ 3 weeks later. 
Frozen sections were stained with PECAM-1 and S100b antibodies. (b) Representative GFP-
labeled PECAM-1+ and PECAM-1- tumors are shown. Sections were stained with PECAM-1 or 
VE-Cadherin antibodies where indicated. The boxed regions shown at far right are zoomed 
regions taken from these images. In the top panels, asterisks indicated tumor cell-lined 
“channels”. The arrows show luminally-positioned tumor cells. In the bottom panels, the 
asterisks and arrows indicate where host-derived VE-cadherin+ EC are absent but void space is 
filled by GFP+/PECAM-1+ tumor cells. In PECAM-1-/GFP+ tumors shown for comparison, 
PECAM-1-/GFP+ tumor cells surround a host-derived, VE-cadherin+ vessel but do not 
incorporate into the lumen. (long scale bars = 100 μm, short = 20 μm) 
  
 67 
 
  
 68 
Figure 2.5. PECAM-1+ melanoma cells form primitive but perfused vascular structures. 
(a) 3,3’ diaminobenzidine (DAB) detection of GFP antibodies used to stain tumors. Unlabeled 
B16F10 tumors implanted in wild type hosts were used as negative controls. Two large blood 
vessels are visible in the center of field. Unlabeled PECAM-1- tumors implanted in a GFP host 
showed an expected staining pattern of host-derived blood vessels (black arrow heads) and 
stromal cells. PECAM-1+/GFP+ tumor cells contained large “holes” and channels, some of which 
were blood-filled. GFP+ tumor cells in right two panels appear to be in direct contact with red 
blood cells (asterisks). The boxed area in the third panel is magnified on far right. Tumor area is 
marked with a “T” and the overlying mouse skin (GFP-) is marked with an “S.” Lower panel 
shows a second PECAM-1+ clone (clone A2) with PECAM-1+/GFP+ tumor cells closely aligned 
with host blood vessels. Some unstained endothelial cell nuclei are also visible and are marked 
with white arrowheads. (b) H & E stained sections of PECAM-1- and PECAM-1+ tumors reveals 
large areas of hemorrhage and vessel dilation. Sections from individual tumors were analyzed 
using ImageJ and are plotted. Sample means were statistically significant as determined by a 
student’s t-test (p=0.0384) (n = 5 tumors). (c) Tumor vascularity was measured using 3D 
acoustic angiography imaging in regions of interest. Means were statistically significant using a 
Welch two sample t-test (p=0.003), n = 9 for PECAM-1- tumors and n = 8 for PECAM-1+ 
tumors. Area-normalized relative blood volume was calculated from 2D destruction-reperfusion 
imaging. A linear mixed-effects model was used to calculate statistical significance (p=0.0182). 
(d) TR-Dextran was injected intravenously in mice bearing GFP-labeled PECAM-1- or PECAM-
1+ tumors. Harvested tumors were sectioned and imaged on a confocal microscope. Red 
arrowheads point to GFP+/TR-Dextran+ areas (n = 4). Ten separate fields from tissue sections 
from each mouse were used to quantify number of tumor cells in contact with the circulation as 
shown. Means were statistically significant using an unpaired two tailed t-test, p < 0.0001. (scale 
bars = 100 μm, short bars in high-magnification panels = 20 μm, error bars = s.e.m.)  
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Figure 2.6. AP-2α is diminished in PECAM-1+ tumor cells and is a transcriptional 
repressor of PECAM-1. 
(a) Semi-quantitative RT-PCR analysis of Ap-2α and Ets transcription factors in PECAM-1- and 
PECAM-1+ clones. (b) Chromatin immunoprecipitation using B16F10 tumor cells. Purified 
genomic DNA was incubated with AP-2α antibodies followed by capture on protein-G agarose. 
Samples were analyzed by semiquantitative RT-PCR using two primer sets predicted to amplify 
different regions of the mouse PECAM-1 promoter (indicated by arrow heads). (c) siRNA 
knockdown of Ap-2α. Cells were incubated for 48 hours with 100 nM of either scrambled 
control (Scr. siRNA) or Ap-2α siRNA. Cell extracts were then evaluated by RT-PCR and 
western blotting. (d) Images of tube forming assay in a PECAM-1- clone following Ap-2α 
siRNA knockdown. Images were taken approximately 16 hours after seeding on Matrigel. 
Quantification of tube-forming ability following Ap-2α siRNA knockdown on right. Results are 
statistically significant where indicated by an asterisk (p<0.0001 by unpaired t-test, n = 12 
observations from individual wells). (e) Lentiviral over-expression of Ap-2α in PECAM-1+ 
clones. Stable cell lines were established from clonal populations following Ap- 2α introduction 
and selection in Zeocin. Cell extracts were evaluated by RT-PCR and western blotting. (f) 
Images of tube forming assay in a PECAM-1+ clone following Ap-2α lentiviral introduction. 
Images were taken approximately 16 hours after seeding on Matrigel. Quantification of tube-
forming ability following Ap-2α lentiviral introduction on right. Results are statistically 
significant where indicated by an asterisk and were confirmed using two different derived clones 
(p=0.0202, n = 3-4 observations from individual wells). (scale bars = 100 μm, error bars = 
s.e.m.)  
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Figure 2.7. PECAM-1+ tumor cells are enriched in tumors challenged with anti-VEGF 
therapy. 
(a) Experimental design. (b) Tumor volumes in control (n = 8) and MCR84-treated (n = 8) mice 
measured with calipers each day. MCR84 treatment was initiated where indicated. (c) Flow 
cytometry analysis of collagenase-dispersed tumors from control and MCR84-treated mice. 
Three representative dot plots from individual mice are shown. Live cells/GFP+ cells were 
selected and then gated for PECAM-1. The top three panels are controls and the bottom three 
panels are MCR84-treated mice. (d) Quantification of tumor subpopulations from collagenase-
dispersed tumors using flow cytometry (n = 5-7 mice/group). Results are statistically significant 
where indicated with an asterisk (left, p=0.0095; center, p=0.0361; right, n.s. = not significant) as 
evaluated by unpaired t-test. (e) Tumor growth in mice bearing PECAM-1- tumors (clone A1) or 
PECAM-1+ tumors (clone A5) challenged with MCR84. Drug treatment was initiated on day five 
and tumor sizes were measured each day with calipers (n = 4-5 mice per group). (f) H & E and 
GFP-stained tissue sections from MCR84-treated PECAM-1- and PECAM-1+ tumors. Yellow 
arrows identify dense pockets of PECAM-1+ tumor cells surrounding a vessel lumen (also 
identified by asterisks in the accompanying GFP-stained section). (scale bars = 100 μm, error 
bars = s.e.m.)  
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Figure 2.8. Human melanoma contains a PECAM-1+ subpopulation that displays vascular-
like characteristics. 
(a) Microarray analysis of normal human melanocytes (black bars) and human melanoma (red 
bars). Each cell line and the raw fluorescence intensity value from the microarray are listed in 
Supplementary Table 2. The dotted horizontal line on the graph is the threshold below which no 
PECAM-1 transcripts are detected. (b) Quantitative real-time PCR analysis of PECAM-1 and 
VE- CADHERIN expression in normal melanocytes and seven of the highest PECAM-1-
expressing cell lines predicted from the microarray. Except for WM1158, no VE-CADHERIN 
transcripts were detected. Human endothelial cells (hEC) were used as a positive control. (c) 
Flow cytometry of selected cell lines stained with human-specific PECAM-1 antibodies. (d) 
Time-lapse images of tube formation assay using the PECAM-1+ human melanoma cell line 
SBCl2 incubated with either a non- specific IgG (top row) or PECAM-1-blocking antibody 
(bottom row). Far right: PECAM-1 blocking antibodies reduce tube formation by ~ 60% in 
PECAM-1+ SBCl2 cells. Sample means were statistically significant as determined by a 
student’s t-test (p=0.02, n = 8 wells per condition). (e) PECAM-1+ lumens formed by SBCl2 
tumors. The asterisks mark lumens and white arrow head shows PECAM-1+ tumor cells 
positioned at the abluminal surface. Two sections from each tumor were scanned for PECAM-1+ 
lumens and the mean values were plotted on right. (scale bars = 100μm, short bars in high-
magnification panels = 20 μm, error bars = s.e.m.) 
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Supplementary Figure 2.1. PECAM-1 is aberrantly expressed in cultured PECAM-1+ 
melanoma cells. 
(a) PECAM-1+ melanoma cells viewed under fluorescence microscopy in un-enriched B16F10 
cultures. B16F10 cultures were detached with accutase, washed and then labeled with PE-
conjugated PECAM-1 before seeding onto microscope slides. Only rare PECAM-1+ cells are 
labeled. (b) Light microscopy showing distinct colonies (asterisks) of PECAM-1+ tumor cells 
that appeared in B16F10 cultures following 3-4 rounds of enrichment using immunomagnetic 
separation. (c) Confocal analysis of mEC and a PECAM-1+ clone derived from B16F10 
melanoma. The yellow arrow heads in the z-plane identify where PECAM-1 expression appears 
distributed throughout that cytoplasm, rather than concentrated at the cell membrane. (d) 
PECAM-1 tyrosine phosphorylation in PECAM-1+ tumor cells and mEC. PECAM-1 was 
immunoprecipitated from whole cell extracts. Western blots were probed with a pan-PECAM-1 
antibody followed by a 4G10 antibody which recognizes phosphorylated tyrosine. (scale bar = 
100 μm) 
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Supplementary Figure 2.2. Tumor cell PECAM-1 expression is stably maintained in vivo 
and in vitro. 
(a) RT-PCR analysis of PECAM-1 expression in parental B16F10 and in a PECAM-1+ clone 
when cells were cultured in standard growth medium (DMEM/FBS) or in an endothelial growth 
medium (EC medium). (b) Flow cytometry of PECAM-1 expression in clone A5 when cells 
were cultured in different growth medium and detached with accutase or detached from tissue 
culture dishes using trypsin. (c) PECAM-1 expression is stable in a PECAM-1+ clone (clone A5) 
when cells are serially passaged using accutase for cell detachment. (d) PECAM-1+ clonal cells 
show slight growth delay compared to PECAM-1- counterparts both in vitro (as measured by 
XTT assay) and in vivo. Tumor growth curves represent one million tumor cells measured daily 
by calipers (n = 5 mice per group). (e) Flow cytometry for PECAM-1 expression in PECAM-1+ 
(clone A5) and PECAM-1- (clone A1) melanoma cells in vitro. Cells were harvested with 
accutase and analyzed at day 0 and then again 90 days later after routine culturing. (f) Flow 
cytometry for PECAM-1 expression by PECAM-1+/GFP+ and PECAM-1-/GFP+ tumor cells in 
vivo. Harvested tumors were dispersed with collagenase and then stained with PECAM-1 
antibodies. Gating on GFP+ tumor cells shows that PECAM-1+ tumor cells generate PECAM-1+ 
progeny whereas PECAM-1- tumor cells generate PECAM-1- progeny. Results were averaged 
and graphed from three mice as shown at far right. (error bars = s.e.m.)  
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Supplementary Figure 2.3. Karyotype analysis of a PECAM-1- and a PECAM-1+ clone 
derived from B16F10 melanoma.  
Karyotypes were obtained from 21-22 metaphase spreads of PECAM-1+ and PECAM– clonal 
populations. Five cells were chosen at random from each cell line. Clone A1 (PECAM-1-) and 
A5 (PECAM-1+) appear to be related, as seen in their similar ploidies (both are hypertriploid), 
and numerous shared numerical and structural abnormalities.  
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Supplementary Figure 2.4. Validation of microarray analysis using qPCR.  
Relative expression is indicated for unsorted B16F10, PECAM-1- (A1), and PECAM-1+ (A2 and 
A5) clones. mEC were used as a positive control. (error bars = s.e.m.)  
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Supplementary Figure 2.5. PECAM-1+ melanoma cells from ΔBraf/Pten-/- tumors do not 
express ICAM1/CD54. 
(a) Flow cytometry analysis for ICAM1 expression in PECAM-1+ clones derived from B16F10. 
(b) PECAM-1+ cells (clone A2) derived from B16F10 tumors express ICAM1 mRNA whereas 
PECAM-1+ cells derived from ΔBraf/Pten-/- cells do not. (error bars = s.e.m.)  
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Supplementary Figure 2.6. Engraftment of PECAM-1+ tumors in PECAM-1 KO mice 
reduces vascular hemorrhage. 
(a) Three representative images from PECAM-1+ tumors engrafted in WT mice (a-c) or 
PECAM-1+ tumors engrafted in PECAM-1 KO mice. (b) Hemorrhage area was quantified as 
described in the methods section (n = 8-9 fields per group, p < 0.05 using a one-tailed Student’s 
t-test). (c) Confirmation of PECAM-1 KO using PECAM-1 immunohistochemistry in PECAM-
1- tumors engrafted in WT or PECAM-1 KO mice. (scale bar = 100 μm, error bars = s.e.m.)  
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Supplementary Figure 2.7. Confocal analysis of GFP+/TR-Dextran+ vascular structures 
using an additional PECAM-1+ clone (clone A2). 
(a) Clone A2 PECAM-1+ tumors perfused with TR-Dextran. Representative images of vessel-
like structures are shown. GFP+/ TR-Dextran cell contact is shown by asterisks and arrows. (b) 
Still images showing 3D slices through magnified portion of vessel outlined by the white box 
above. The image was rotated along the z-axis ~ 180 degrees through panels. (scale bar = 20 μm)  
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Supplementary Figure 2.8. Transmission electron microscopy of PECAM-1+ tumor cells in 
contact with erythrocytes. 
Top row: A PECAM-1- tumor showing electron-dense basal lamina (yellow arrows) and an 
endothelial cell body (E) juxtaposed to erythrocytes (R), while no melanasome-containing cells 
are evident. Remaining rows: PECAM-1+ melanoma cells were frequently found in close 
proximity to or directly abutting the basal lamina. Melanasome (black arrows) containing cells 
were frequently found in direct contact with the endothelium or basal lamina. Additionally, we 
found instances where a melanosomes-containing cell process appears to infiltrate into the basal 
lamina (bottom panel: boxed region), suggesting these cells could interdigitate with the 
endothelium in these vessels. (scale bar: left column (top to bottom) 2 μm, 1 μm, 1 μm, 0.5 μm. 
Right column (top to bottom) 1 μm, 0.5 μm, 0.5 μm, 0.5 μm)  
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Supplementary Figure 2.9. Additional characterization of PECAM-1- and PECAM-1+ 
melanoma cells. 
(a) PECAM-1 expression is not induced in B16F10 tumor cells upon treatment with 5-aza or 
TSA. Cells were treated for seven days at the indicated concentrations (nM). (b) Expression of 
additional melanoma markers and PECAM-1 in PECAM-1- and PECAM-1+ clones. (c) 
Melanoma markers DCT (~ 50kDa) and MITF (~ 60kDa) migrate at their predicted sizes by 
western blotting. Blots were stripped and reprobed with β-actin antibodies to show equal 
loading. (d) PECAM-1+ tumor cells typically produced more pigment than their PECAM-1- 
counterparts in culture. (e) Tumors derived from PECAM-1+ tumor cells were more pigmented 
than their counterparts. (scale bars = 1 cm)  
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Supplementary Figure 2.10. Specificity of human-specific versus pan-species PECAM-1 
antibodies. 
(a) Western blotting of EC lysates using human specific (Hu) and human/mouse-specific 
(Hu/mo) PECAM-1 antibodies. Note that there is no cross-reactivity of the human-specific 
antibody with mouse EC. Blots were stripped and re-probed with β-actin antibodies to show 
equal loading. (b) Human-specific PECAM-1 antibodies used for immunohistochemistry of 
mouse B16F10 or human SBCl2 tumors engrafted in mice. No specific staining was detected in 
B16F10 tumors and only background autofluorescence from red blood cells (R) was observed. 
The inset is a zoomed image showing distinctive membrane/cytoplasmic PECAM-1 staining in 
SBCl2 tumors. (scale bar = 100 μm)  
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Tables 
Supplementary Table 2.1. Table of PCR primers.  
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Supplementary Table 2.2. Table of human cell lines. 
Human melanoma cell lines (left) and normal human melanocytes (right) and raw PECAM-1 
fluorescence values from microarray are listed.  
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Supplementary Table 2.3. Table of antibodies and dilutions.  
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CHAPTER 3: Conclusions and Future Directions3 
Summary of results 
We have identified a subpopulation of PECAM-1+ melanoma cells that was “hidden” 
within heterogeneous and predominantly PECAM-1- melanoma tumors. Initial gene expression 
and western blot results revealed this subpopulation of cells expressed the endothelial selective 
marker PECAM-1, as well as other endothelial markers including Icam1, but lacked other 
canonical endothelial markers, and expressed several melanoma genes including Tyr and Dct. 
We were able to confirm that the PECAM-1+ subfraction existed as a stable (~0.2%) yet minor 
population within B16F10 tumors, and ruled out the possibility of cell fusion with host 
endothelial cells by retrieving GFP+/PECAM-1+ tumor cells from wildtype mice.  
Single-cell cloning revealed that PECAM-1 expression by B16F10 was stable, as clones 
retained ~99-100% positivity over time. Furthermore, these clones adopted an “endothelial-like” 
phenotype in vitro. When plated on Matrigel they formed a branched tube-like structure, a 
hallmark of endothelial cells and VM-competent tumor cells. Importantly, this phenotype was 
blocked with PECAM-1 blocking antibodies, confirming it was at least partially PECAM-1-
dependent. This is consistent with data in mesothelioma cells where forced overexpression of 
PECAM-1 caused a tube-formation phenotype in similar conditions (Cao et al. 2002). These data 
were further supported by knockdown and overexpression studies, as PECAM-1-KD repressed 
                                                
3 Chapter 3 is adapted in part from Dunleavey, J.M. et al. Vascular channels formed by 
subpopulations of PECAM1+ melanoma cells. Nature Comm. 5. 1-16. (2014) 
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tube formation in PECAM-1+ cells and PECAM-1-OE enhanced tube formation in PECAM-1- 
cells. 
We found that the in vitro vascular-like phenotype of PECAM-1+ melanoma translated 
into a striking in vivo vascular phenotype. Clonally derived PECAM-1+ melanoma displayed 
large blood-filled channels, which were not observed in PECAM-1- counterparts. Furthermore, 
PECAM-1+ melanoma cells, when labeled with GFP and observed under fluorescence 
microscopy, appeared to be present at the edge of blood vessels and in close proximity to 
endothelial cells. High-resolution confocal microscopy and transmission electron microscopy 
revealed that these cells appear to affiliate with endothelial cells and were in direct contact with 
the perfused vasculature, suggesting that the vascular-like phenotype of these cells allowed them 
to interact with the luminal surface of blood vessels. Supporting this hypothesis, when 
PECAM1+ tumor cells were engrafted into PECAM-1-KO mice, large, blood filled channels 
were lost compared to tumors formed in WT mice. Taken together, these data suggest that 
PECAM-1+ melanoma engage in PECAM-1-dependent VM. 
We determined the mechanism for PECAM-1 expression in melanoma was governed by 
the transcription factor AP-2α. PECAM-1+ melanoma exhibited a striking loss of AP-2α 
expression, and AP-2α was found by ChIP to bind the PECAM-1 promoter. siRNA targeting of 
AP-2α upregulated PECAM-1 expression in PECAM-1- clones and whereas ectopic expression 
of AP-2α blocked PECAM-1 expression in PECAM-1+ clones. 
 Melanoma appears to display a spectrum of PECAM-1 expression and PECAM-1-
positive tumor cells were present in a fraction of human tumors. We were also able to isolate and 
purify PECAM-1+ melanoma cells from a genetically modified mouse model of melanoma. 
Twenty-five percent of human melanoma cell lines expressed higher levels of PECAM-1 than 
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normal human melanocytes. These human PECAM-1+ melanoma displayed in vitro tube 
formation in the same manner as our mouse models. When we engrafted the human clone with 
the highest basal PECAM-1 expression into NSG mice, we found what appeared to be blood 
vessels in the resulting tumors with human tumor cells expressing human PECAM-1 
incorporated. 
 We found that when unsorted B16F10 melanoma were engrafted into mice and 
challenged with an anti-VEGF therapeutic analog, PECAM-1+ melanoma was enriched ~6-fold. 
PECAM-1+/VEGFR-2- cells therefore might supplant vascular EC that are lost following 
treatment with anti-angiogenic therapy and form PECAM-1-dependent “bridges” between tumor 
cells and neighboring EC (Fig. 3.1a, b). Supporting this hypothesis, clonal populations of 
PECAM-1+ melanoma were refractory to VEGF inhibition, while PECAM-1- melanoma 
displayed similar growth dynamics to unsorted B16F10 when challenged with a VEGF inhibitor. 
Future Directions 
Future studies on PECAM-1 expression by melanoma 
The expression of PECAM-1 by melanoma cells may represent a new form of VM. Our 
model suggests that PECAM-1-dependent VM may differ from previously described models in 
which tumor cell- to -EC mosaicism was a passive process where tumor cell-endothelial contacts 
were transient and weak (Chang et al. 2000; di Tomaso et al. 2005). Instead, expression of 
PECAM-1 by tumor cells may serve to actively stabilize cell-cell interactions between PECAM-
1+ tumor cells and EC. PECAM-1 is typically concentrated at cell-cell borders by a process 
known as “diffusion trapping” which leads to aggregation of PECAM-1 protein at sites where 
two PECAM-1+ cells meet (Sun et al. 2000; Feng et al. 2004). Homophilic binding of PECAM-1 
between immunoglobulin domains 1 and 2 (IgD1/2) has been shown to strengthen endothelial 
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barriers, and can be increased by ligand binding at the Ig6 domain of the extracellular region 
(Mei et al. 2014; Paddock et al. 2016; Privratsky et al. 2011) Indeed, homophilic PECAM-1-
PECAM-1 binding was suggested, many years ago, to underlie in vitro tumor cell adhesion to 
EC in co-culture studies (Tang et al. 1993). Furthermore, PECAM-1 is required for tube 
formation, as PECAM-1 blocking antibodies reduced the tube formation ability of PECAM-1+ 
melanoma cells, similar to what has been observed in cultured EC (DeLisser et al. 1997). 
Notably, PECAM-1 overexpression in mesothelioma cells, which do not express PECAM-1, 
induces robust tube formation on Matrigel. PECAM-1 is required for tube formation in bona fide 
EC, whereas VE-cadherin mediates both cell-cell adhesion and vacuole fusion (Yang et al. 
2010). Thus, PECAM-1 expression in melanoma may mediate cell elongation, migration, and 
invasion while stabilizing the junctional, homophilic complexes between neighboring cells that 
are necessary to create a patent lumen. Future experiments on homophilic PECAM-1 binding 
between tumor cells and endothelial cells in vitro as well as in tumors, through imaging or 
traditional barrier function studies (Privratsky and Newman 2014) could help explain whether 
PECAM-1 homophilic binding is definitively taking place in our model of VM. Additionally, a 
novel recent method described by the Newman group allows for interrogation of EC with 
individual PECAM-1 molecules attached to lipid nanodiscs (Mei et al. 2014). In a cell-free 
manner, we could adapt these nanodiscs to contain melanoma-derived PECAM-1 and determine 
binding efficiency with cultured EC, to see if melanoma-derived PECAM1 displays binding 
differences. These experiments could provide insight into whether current PECAM-1-blocking 
reagents could be adapted to inhibit tumor cell-EC affiliation.  
PECAM-1 has well-known functions in shear stress signaling in the mature blood 
vasculature. Shear stress has been demonstrated to trigger the tyrosine phosphorylation of 
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PECAM-1 leading to a signaling cascade that includes Akt and eNOS (Tzima et al. 2005; 
Newman 2003). We found that PECAM-1 expressed in melanoma displays similar patterns of 
phosphorylation as cultured EC, but whether this has consequences for signaling in these 
melanoma is unclear. Of note, the PECAM-1 protein detected in our study appeared to be the 
same molecular weight as PECAM-1 derived from EC, suggesting that the species is mature, 
full-length PECAM-1 including the extra- and intra-cellular domains.  An interesting course of 
study would be to determine whether the intracellular ITIM-domain-binding proteins including 
SHP2, PI3K and β-catenin (reviewed in depth by P.J. Newman (Newman 2003)) bind PECAM-1 
in melanoma as they do in EC, and whether these signaling pathways are differentially regulated 
in PECAM-1+ melanoma compared to PECAM-1- clones. This of particular interest as PI3K and 
Akt are thought to contribute to a pro-survival phenotype, which if activated in a subpopulation 
of melanoma could contribute to long term survival of the tumor (Liu et al. 2009; Ojesina et al. 
2014).    
Another prominent feature of PECAM-1 signaling is suppression of apoptosis, which 
could offer a competitive survival advantage to a tumor comprised of a heterogeneous mixture of 
tumor cells that include a PECAM-1+ fraction (Gao et al. 2003; Bergom, Gao, and Newman 
2005). Specifically, when PECAM-1was overexpressed in HEK293 cells and mesothelioma 
cells, cells became resistant to the DNA-damaging agent etoposide (Bergom et al. 2006). 
Furthermore, forced expression of the pro-apoptotic TNFα receptor on cultured endothelial cells 
activated PECAM-1, which counteracted the pro-apoptotic signaling by activating Akt (Cheung 
et al. 2015). This signaling is independent of the homophilic binding capacity of PECAM-1, and 
appears to be dependent on the C-terminal intracellular domain of the molecule (Bergom et al. 
2008). These studies suggest a potential role for PECAM-1 expression by tumor cells as an 
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inhibitor of apoptosis and prospective mechanism for resistance to cytotoxic chemotherapy. It 
would be extremely interesting to interrogate B16F10 tumors as well as PECAM-1+ and 
PECAM-1- clonal populations derived from this cell line with current chemotherapeutics. If 
PECAM-1 serves as an apoptotic suppressor in these cells. I speculate that drug-resistant 
unsorted B16F10 would display an increase in PECAM-1+ tumor cells compared to control, and 
that PECAM-1+ clonal melanoma may display intrinsic resistance to these agents. 
An important question raised by our work is whether PECAM-1 represents a potential 
target for therapy, either in conjunction with traditional cytotoxic chemotherapies or in 
combination with existing anti-angiogenesis strategies. Because of its importance in shear stress 
signaling and responses to atherogenic stimuli, many groups are interested in blocking PECAM-
1 signaling (Dasgupta et al. 2010). Importantly, preclinical modeling found that PECAM-1-KO, 
as well as WT mice treated with PECAM-1 blocking antibodies displayed reduced metastatic 
progression and cachexia (DeLisser et al. 2010). Interestingly, this study used and found striking 
inhibition of metastasis with the B16F10 cell line, which we describe harboring a PECAM-1+ 
subfraction that engages in PECAM-1-dependent VM. While the authors of the blocking study 
did not examine VM in their model, as our findings were not yet published, it stands to reason 
that PECAM-1 blockade would also block the PECAM-1-dependent VM. As a corollary to this, 
a recent high-profile study found that VM-competent cells allow for direct dissemination of 
tumor cells into the vasculature and promoted metastatic seeding (Wagenblast et al. 2015). 
Taken together, these two studies suggest that VM can promote metastasis and B16F10 
metastasis is blocked, at least partially, by PECAM-1 blockade. Combined with our data 
showing PECAM-1-dependent VM in B16F10, this suggests that blocking VM may in fact 
reduce metastasis.  
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An important role for PECAM-1 is in diapedesis, or the extravasation of circulating 
leukocytes from the blood vasculature. PECAM-1 is expressed in both immune cells and EC, and 
has been shown to regulate the early stages of leukocyte tethering. It is thought that PECAM-1 
acts as an early tether which engages circulating leukocytes, brings them adjacent to the vessel 
wall, and allows the engagement of other adhesion molecules like CD99 (Torzicky et al. 2012). 
An interesting question is whether VM-engaging tumor cells, particularly those expressing 
PECAM-1, may contribute to the recruitment of tumor infiltrating leukocytes (TILs). Tumor-
associated M2 macrophages are thought to be a key mediator of tumor progression, and secrete a 
pro-inflammatory cytokine mixture that has been shown to partially fuel tumor growth (Quail 
and Joyce 2013; Lança and Silva-Santos 2014). We did not observe major differences in immune 
cell infiltration in PECAM-1+ or PECAM-1- tumors (data not shown), but did not exhaustively 
address this question. However, when  PECAM-1 was blocked either genetically or with an 
antibody, metastasis was reduced but no difference in macrophage infiltration was observed 
(DeLisser et al. 2010). These data suggest that while PECAM-1 has an important, but 
dispensable role in canonical diapedesis, especially in inflammation-related responses 
(Nourshargh, Krombach, and Dejana 2006; Duncan et al. 1999; Thompson et al. 2001) the 
contribution of PECAM-1 to immune cell infiltration into the tumor may be limited, regardless 
of whether it is expressed on EC or in tumor cells. However, it would be interesting to revisit 
recent studies investigating metastatic mechanisms using the B16F10 model to determine if 
PECAM-1+ melanoma are involved (Peinado et al. 2012). It is possible that if PECAM1 is not 
altering immune cell infiltration that perhaps it allows for a tumor-cell “diapedetic mimicry” 
where tumor cells use PECAM1 to adhere to the vessel wall like immune cells and improve 
extravasation and seeding. Supporting this, VM-competent cells in a recent study were shown to 
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improve metastatic seeding by increasing tumor cell contact with blood flow (Wagenblast et al. 
2015), which could be augmented by tumor expression of pro-extravasatory factors.    
Lastly, we found that PECAM-1+ melanoma displayed a slight growth delay compared to 
PECAM-1- counterparts. It may be possible that the acquisition of vascular-like characteristics 
comes at the expense of reduced tumorigenicity, or that perhaps signaling through PECAM-1 
may represent a form of contact inhibition and a slower rate of growth despite the cells’ ability 
form vascular-like channels. 
Gene expression in PECAM-1+ melanoma 
 We found a distinct gene signature in PECAM-1+ melanoma which included both 
endothelial selective markers as well as a host of other genes. It is unclear what role, if any, these 
genes may play in the VM phenotype. Of note, from our microarray analysis, we found that Slpi, 
a gene recently implicated in VM in breast cancer, appeared upregulated, as well as the serine 
protease inhibitor Pai-1 (Serpine1), a related family member of another VM-involved gene 
Serpine2 (Buchholz et al. 2003), which was implicated in VM in the same study (Wagenblast et 
al. 2015). As the involvement of these genes in VM was unknown while we were performing our 
study, it would be interesting to determine whether they contribute to the PECAM-1-dependent 
form of VM we have described. Blocking PECAM-1 in our hands reduced tube formation by 
~50%, and a redundant mechanism for VM formation could explain the lack of a binary response 
in these assays. Knockdown or knockout of these genes individually, or in conjunction with 
PECAM-1 blockade, could help determine what role, if any, they play in PECAM-1-mediated 
VM. As a corollary to this, another course of study could be to examine the role other genes 
identified in our array play in VM or tumor progression. We identified a number of genes with 
known endothelial function that were upregulated in PECAM-1+ melanoma including 
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CD54/ICAM1 and thrombospondin 1 (Thbs1) . Whether these genes are involved in VM is 
unknown, but current tools for modulating gene expression would allow for relatively easy gene 
knockout of interest using CRISPR/Cas9 (Ran et al. 2013). Thbs1 is a particularly interesting 
gene for study in these cells, as upregulated Thbs1 has been shown to inhibit tumor growth,and 
can promote dormancy or quiescence in metastatic microvascular niches (Lawler 2002; Ghajar et 
al. 2013). We noted that PECAM-1+ melanoma grow more slowly than PECAM-1- clones, and 
these data could be explained by increased levels of the Thbs1.  
AP-2α loss in PECAM-1+ melanoma: implications for aggressiveness 
AP-2α is a putative tumor suppressor which slows or blocks tumor cell growth in 
melanoma (Bar-Eli 1999), glioblastoma (Heimberger et al. 2005), prostate (Ruiz et al. 2001; 
Ruiz et al. 2004), breast (Bosher, Williams, and Hurst 1995) and colon (Li, Löhr, and Dashwood 
2009). Previous studies in melanoma have shown AP-2α acts as a transcriptional repressor of 
melanoma cell adhesion molecule (MCAM), activator of KIT, PAR-1, and VEGF (Jean et al. 
1998; Huang et al. 1998; Ruiz et al. 2004). Importantly, loss of AP-2α has been shown to be a 
key regulator of the shift from the radial growth phase (RGP) of melanoma to the vertical growth 
phase (VGP) (Mobley et al. 2012) and is correlated with melanoma aggressiveness 
(Gershenwald et al. 2001; Huang et al. 1998). AP-2α also controls melanoma cell motility and its 
expression is diminished in aggressive forms of melanoma and breast cancer (Karjalainen et al. 
1998; Pellikainen et al. 2002). While PECAM-1 was not previously described as a target gene 
for AP-2α, the loss of this factor in PECAM-1+ melanoma is extremely interesting. First, we 
have described a novel negative regulator of PECAM-1 expression, whose transcriptional control 
remains relatively unclear (Gumina et al. 1997). Several transcription factors have binding sites 
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in the PECAM-1 promoter, but to our knowledge AP-2α is the first transcription factor shown to 
repress PECAM-1 signaling directly.  
Although the focus of our study was on PECAM-1 expression by melanoma, other 
transcriptional targets of AP-2α were identified by our microarray analysis. Specifically, Id1, 
which is regulated by the AP-2α target MCAM (Zigler et al. 2011), and plasminogen activator 
inhibitor-1 (Pai-1) (Bar-Eli 1999) were both upregulated in PECAM-1+ melanoma as determined 
by microarray. Characterizing whether the loss of AP-2α in fact drives these altered gene 
expression changes would allow us to determine whether adoption of PECAM-1 expression is 
part of the spectrum of increased melanoma aggressiveness, and is worthy of further analysis.  
 While we identified a mechanism for AP-2α-mediated repression of PECAM-1, how AP-
2α is lost in a subpopulation of B16F10 remains unclear. It is possible that signaling upstream of 
AP-2α is controlling its loss. It is known that CREB/cAMP is capable of downregulating AP-2α 
in melanoma (Melnikova et al. 2010). While we did not assay cAMP activity in our study, 
determining the status of cAMP signaling or whether differentially regulated G-protein coupled 
receptors are activating CREB through PKA would allow us to understand if CREB is 
modulating the phenotype we observed in PECAM-1+ melanoma. Furthermore, a recent interest 
across cell biology is post-transcriptional regulation of gene expression by microRNA (miRNA) 
species. A recent study found that mir-214 indirectly represses AP-2α expression, and was 
dubbed a potential “melano-miR” (Bar-Eli 2011; Penna et al. 2011). Whether similar repression 
of AP-2α in PECAM-1+ melanoma occurs is not known, but our lab and others have recently 
adopted the NanoString microarray which allows for screening of miRNA species. This could 
allow us to ask which miRNAs are differentially regulated in PECAM-1+ clones compared to 
negative counterparts.  
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Tumor cell-derived PECAM-1: mechanisms for resistance to anti-angiogenic therapies? 
In CHAPTER ONE I addressed the current state of anti-angiogenesis strategies either in 
the clinic or in development. Briefly, strategies targeting the VEGF axis, and to a lesser extent, 
Ang/Tie2 signaling have been largely disappointing. While new drugs including pazaponib and 
nintendanib which exhibit multikinase inhibition, including FGFRs and PDGFRs, have promise, 
it remains to be seen whether targeting the endothelium through growth factor receptor inhibitors 
will be successful. Of note, practically no success has been seen in melanoma patients with 
regard to anti-angiogenic strategies (Kim et al. 2011). Why melanoma resists these therapies 
remains an open question, but one hypothesis is that as a relatively well-vascularized organ and 
the long period of development of skin lesions, melanoma may not rely on VEGF-mediated 
angiogenesis for sustained growth (Helfrich et al. 2010). Vessel co-option and expansion via 
non-angiogenic means could provide these tumors an innate resistance to anti-angiogenic agents.  
 We found a population of melanoma cells which was able to actively affiliate with the 
endothelial cells of blood vessels. Whether VM aids the co-optive phenotype seen in many non-
angiogenic tumors is unknown, but the prevalence of VM in melanoma could provide a 
mechanism for tumors to affiliate more closely with pre-existing endothelium. Advances in in 
vivo imaging could allow us to model nascent tumors and visualize tumor cells and perfused 
blood with molecular dyes. Perhaps using intravital imaging we could identify VM in living 
tumors, and determine whether PECAM-1+ tumor cells allow for increased vessel cooption. 
Furthermore, we could treat mice with inhibitors of angiogenesis and observe the dynamics of 
vessel response. The ability to image tumors in vivo to monitor responses to anti-angiogenic 
strategies would allow us to determine how PECAM-1+ tumor cells contributed to resistance, and 
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test our hypothesis that these cells supplant vulnerable endothelial cells in the face of VEGF 
inhibition.  
 Perhaps the most pressing question raised by our findings is whether PECAM-1 
represents a new druggable target for treatment of solid tumors (Debs, patent.), particularly 
melanoma. As I noted previously, relatively little has been done in the field of tumor biology to 
target PECAM-1. Currently, just two studies in mice have extensively looked at PECAM-1 
blockade and found that in mouse models blocking PECAM-1 reduced late-stage metastatic 
growth as well as primary tumor burden, and noted decreased tumor angiogenesis (Zhou et al. 
1999; DeLisser et al. 2010). These studies each used the B16F10 model, and it is possible that 
part of the response to treatment came from inhibition of PECAM-1-dependent VM. PECAM-1 
represents an attractive target, as it is dispensable in development and adult animals, with defects 
in inflammation and atherosclerosis being the major adult phenotypes (Duncan et al. 1999). 
Furthermore, as a cell-surface molecule, PECAM-1 can be and has been targeted by antibodies, 
which have become a major targeting tool in cancer therapy. Our findings suggest that perhaps 
targeting PECAM-1 alongside traditional anti-angiogenic agents will result in better response to 
therapy, particularly in tumors which possess PECAM-1+ subfractions. However, before 
PECAM-1 could be considered as a target, larger-scale screens for PECAM-1 positivity need to 
be completed. While we found ~25% of the human melanoma cell lines we screened possessed 
higher-than-basal levels of PECAM-1, large-scale genomics datasets of primary patient samples 
should be examined as well. If PECAM-1 is broadly expressed in a large percentage of human 
patients, then development of human-tolerated anti-PECAM-1 blocking antibodies could 
improve the efficacy of anti-angiogenesis therapy, and provide more tools for the new era of 
individualized medicine.  
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Figures 
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Figure 3.1. A model for a PECAM-1-dependent form of vasculogenic mimicry. 
(a) PECAM-1 plays a well-characterized role in stabilizing junctions between EC and leukocytes 
and between two EC. Tumor cell expression of PECAM-1 may also stabilize interactions 
between tumor cells (TC) and EC or between two PECAM-1+ TC to form stable junctions. (b) In 
tumors where PECAM-1+ tumor cells are present, VEGF-independent “bridges” would not be 
affected by anti-VEGF therapies and could supplant host endothelium following VEGF 
inhibition. “Channels” formed exclusively by PECAM-1+ TC could also be insensitive to VEGF 
blockade.  
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